>
India's health system goes digital: 700 million ABDM identities, AI in the district hospital, and the DPDP reckoning ahead.
Volge Quarterly is Volge's signature series, published every quarter for enterprise customers. Each edition takes one subject, sets out where it currently stands on the published record, and makes a set of dated, falsifiable judgements on where it is going, written to give a buyer something firmer than a forecast: every figure carries its source and its date, every judgement carries the date on which it resolves, and the following year's edition grades each one hit, missed or partial.
The market stops paying for growth and starts paying for unit economics. Who survives the reckoning of 2027, and where the value moves next.
Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.
2027 is the year India's digital-health market stops paying for growth and starts paying for unit economics.
The binding constraint in Indian digital health was never regulation, and it was never capital. It is the gap between what a customer costs to acquire and what a customer is worth. A teleconsultation acquired for ₹800–2,000 against a single consultation worth ₹300–800 is a subsidy dressed as a business, and the market spent the better part of a decade funding the subsidy. That era is over. In 2027 the subsidy ends, and the businesses that survive are the ones whose arithmetic already works.
Two kinds of company clear the bar. The first is the multi-segment platform (the Tata 1mg or the PharmEasy) that owns teleconsultation, pharmacy and diagnostics together, so a single acquired customer is monetised across several transactions and the cost of acquisition is amortised rather than absorbed. The second is the business that never paid for acquisition at all: the corporate group-health seller, the provider-software vendor, the venture that rides the ABDM public rails into distribution it did not have to buy. The single-service consumer app, bought one expensive download at a time, is the loser of the year.
This is not a pessimistic read. The market is large (roughly $15–18 billion in 2025) and the structural demand is real: India has about 1.1 doctors per 1,000 people against 2.8 in the developed world, and 70% of its specialists serve the urban third of the population. The opportunity to reach populations that have never had reliable access to quality care is genuine and vast. What changes in 2027 is the discipline with which capital is allocated against that opportunity. Funding has rebounded (about $1.13 billion across 112 deals in 2024) but it now screens for unit economics, not growth, and it has repriced the 2021 cohort without sentiment.
The year's quieter story is where value migrates. It moves down the acuity curve and away from the crowded front door of acute teleconsultation: towards chronic-care management, provider software and the public-rail infrastructure, where retention is higher and margins hold. It moves towards the payer, as health insurance becomes the largest segment of India's
non-life market and group and out-patient cover begin, at last, to relieve the out-of-pocket trap that created the unit-economics problem in the first place. And it moves towards frugal, sovereign artificial intelligence: small, Indic-language, voice-first models that cut the cost to serve and extend the scarce clinician, attacking the one constraint the sector cannot engineer around.
The Calls in this edition put numbers and dates to those movements. They are written to be graded a year from now. Read them as the firm's considered judgement on a sector at an inflection, and as a standing invitation to mark our homework in 2028.
The Editors, Volge Quarterly · 2027
A ~$15–18 billion market chasing $100 billion by 2033, built on the collision of severe healthcare undersupply with mass digital adoption and the ABDM public rails, where unit economics, not regulation, decide survival.
The reconciled basis used throughout this edition, on one page. Where credible sources disagree on scope, a range is given rather than a false point estimate.
Reconciled from Custom Market Insights, Mordor Intelligence, the National Health Authority / ABDM dashboard, IRDAI and industry funding trackers (2024–26). Ranges reflect genuine source disagreement on scope. Current to June 2026. Drawn from Volge's internal sector playbook .
A large, fast-growing market on a broad and shallow base (most of its 11,000 firms sub-scale) where the test that separates winners from the rest is customer-acquisition cost against lifetime value, not market size.
Digital health is software meeting a healthcare system that is large, fragmented and undersupplied, and the present moment is distinct because three conditions have arrived together.
India's digital-health market is estimated at roughly $15–18 billion in 2025 and is projected to exceed $100 billion by 2033, a compound rate in the order of 20–25%. The opportunity rests on a structural condition: severe undersupply of physical healthcare meeting rapid digital adoption and a national public digital-health stack. Unlike medtech, digital health is software (it iterates quickly and scales on modest capital) and its binding constraint is neither regulation nor capital but unit economics.
That distinction organises the whole sector. A device company is gated by clinical validation, regulatory class and manufacturing capital, and it earns over years. A digital-health company faces none of these in the same degree; it can launch on modest capital and iterate weekly. What it cannot escape is the arithmetic of acquisition and retention. Survival turns on lifetime value: repeat use, cross-sell into pharmacy and diagnostics, or a shift to lower-cost business-to-business and government channels.
Capital has rebounded from the 2023 correction, but it is selective, and it now rewards positive unit economics over growth. The winners cluster in platforms that own multiple segments and in the lower-cost channels: corporate, government and infrastructure. The shape of the year follows directly from that sentence.
The chapters that follow take the sector apart in order: the three global models and why India's is distinct; the three forces behind the inflection; the seven-segment taxonomy and each segment's economics; the public rails; the unit-economics test worked through in numbers; the payer problem and its escape route; the regulatory patchwork; the competitive and funding
landscape; the arrival of generative AI; and the verticals beneath the mainstream that are growing fastest.
Three structural models of digital health have emerged worldwide. India's is distinct from both of the others, and the contrast explains both its opportunity and its central difficulty.
The United States runs a payer-led model: established reimbursement codes and a concentrated insurer system underwrite telehealth and remote monitoring, so the monetisation problem is solved by the payer and the binding constraint is cost. China runs a super-app model, in which consumer-internet and insurance conglomerates built closed loops of consultation, pharmacy, delivery and insurance. India runs a public-rails model: the government built the identity and interoperability layer (ABDM) and a national telemedicine service (eSanjeevani), on which private platforms build.
| Market | Model | Monetisation engine | Exemplars |
|---|---|---|---|
| United States | Payer-led | Insurer reimbursement codes | Teladoc; Amazon Health |
| China | Super-app / conglomerate | Closed loop: consult + pharmacy + insurance | Ping An Good Doctor (400M+ users); JD Health; AliHealth |
| India | Public-rails + private platforms | Out-of-pocket; emerging insurance & government | ABDM / eSanjeevani; Tata 1mg; PharmEasy |
Sources: GlobeNewswire (China telemedicine, 2025); company disclosures. China telemedicine is projected at ~$18.9B by 2034. Current to June 2026.
The consequence is precise. Distribution in India is cheaper because the rails are shared, but monetisation is harder because there is no dominant payer. India's defining feature is therefore neither the US payer nor the Chinese super-app, but public infrastructure that lowers the cost of reach while leaving the unit-economics problem unsolved. Every strategic choice in the sector is, at root, an answer to that single asymmetry.
The first condition is structural undersupply: too few doctors, too few beds, and a specialist workforce concentrated in the cities. The second is a digital inflection: more than 800 million internet users and over 500 million smartphone users, with 4G reaching tier-2 and tier-3 cities. The third is policy and capital: the Ayushman Bharat Digital Mission, government telemedicine through eSanjeevani, and renewed investor appetite after the 2023 correction.
Sources: Ministry of Health & Family Welfare; ABDM / National Health Authority; industry reporting. Indicators current to June 2026.
India's digital-health expansion is not incidental. It sits at the intersection of three conditions that have arrived at the same time.
| Condition | Indicator | Significance |
|---|---|---|
| Structural undersupply | ~1.1 doctors / 1,000 (vs 2.8); ~1.5M bed shortage | Demand the physical system cannot meet |
| Specialist concentration | ~70% of specialists serve the urban ~30% | The access gap digital health addresses |
| Digital inflection | 800M+ internet, 500M+ smartphone users | The distribution channel for care |
| Out-of-pocket spend | ~60% of health expenditure | Shapes pricing and the payer problem |
| Public rails | ABDM; eSanjeevani; PM-JAY | Government-built distribution and identity layer |
The conditions describe an opening, not a guarantee. Markets consolidate quickly, unit economics decide which models survive, and regulatory clarity in several segments (e-pharmacy most of all) remains unsettled. First movers with defensible models and durable unit economics win disproportionately; undifferentiated direct-to-consumer entrants do not.
Digital health is wide and fast-moving. To read it coherently this edition commits to a single framework: seven segments on a horizontal layer of public rails, with clinical AI as a cross-cutting capability rather than a peer.
| # | Segment | Definition |
|---|---|---|
| 1 | Teleconsultation & telemedicine | Remote clinical consultation by video, audio or text |
| 2 | E-pharmacy & medicine delivery | Online ordering and fulfilment of medicines |
| 3 | E-diagnostics & lab aggregation | Booking, home collection and reporting of tests |
| 4 | Provider & clinical software | Software sold to hospitals, clinics and doctors |
| 5 | Chronic-care & remote monitoring | Continuous management of long-term conditions |
| 6 | Health & wellness / preventive | Direct-to-consumer preventive health and fitness |
| 7 | Health insurtech & claims | Technology for insurance distribution and claims |
Canonical taxonomy. Two layers sit outside the seven: the public rails (ABDM, eSanjeevani), which are infrastructure; and clinical AI, a cross-cutting capability. Current to June 2026.
The framework is designed to be collectively exhaustive: every digital-health business resolves to one of
the seven, and most platforms combine several. Clinical artificial intelligence is deliberately not a segment of its own: it appears across the seven as triage in teleconsultation, image and report reading in diagnostics, and a feature of provider software. Treating it as a peer would double-count the overlap, so it is read here as a horizontal capability that raises the defensibility of whichever segment it sits within.
Each segment carries a distinct economic and competitive profile, and a thesis should be explicit about which it is buying. The matrix consolidates share, economics, regulation, India's position and the leaders.
| Segment | Share & economics | Regulatory status | India's position | Leading players |
|---|---|---|---|---|
| 1 · Teleconsultation | ~45% of revenue; high CAC, low single-consult value | Telemedicine Guidelines 2020 | Crowded; survival needs repeat or B2B | Practo, Apollo 24|7, MediBuddy, Tata 1mg |
| 2 · E-pharmacy | Largest by revenue; thin margins (15–25%) | Unsettled: draft rules pending since 2018 | Consolidated; scale & logistics the moat | PharmEasy, Tata 1mg, Netmeds, Apollo |
| 3 · E-diagnostics | ~30% with e-pharmacy; capital-intensive | NABL / ISO 15189 accreditation | Growing; logistics & trust the moat | Tata 1mg, Redcliffe, Orange Health, Healthians |
| 4 · Provider software | Recurring SaaS; lower CAC, sticky | ABDM compliance; data governance | Underbuilt; ABDM creates demand | Eka Care, HealthPlix, Practo Ray, Halemind |
| 5 · Chronic-care & RPM | Better economics; recurring | DPDP; device overlap | Promising; higher LTV & retention | BeatO, Fitterfly, Phable, Wellthy |
| 6 · Wellness / preventive | ~10%; D2C, high CAC, brand-led | Light-touch; consumer protection | Crowded; premium positioning needed | HealthifyMe, Cult.fit, Ultrahuman |
| 7 · Insurtech & claims | Fast-growing; ~29% CAGR | IRDAI regulated | Maturing; group health the wedge | Onsurity, Plum, Nova Benefits, Policybazaar |
Shares re-cut from an earlier four-way estimate; provider software, chronic-care and insurtech are not separately quantified. Indicative; current to June 2026.
The pattern is consistent. India is strongest in the recurring, sticky, business-to-business-flavoured segments (provider software, chronic-care, insurtech) and hardest in the crowded, high-acquisition-cost consumer segments, teleconsultation and wellness. Teleconsultation, the largest by revenue, is the most economically difficult: acquisition cost exceeds the value of a single consultation, and it competes against a free public alternative in eSanjeevani. E-pharmacy is the largest by absolute revenue and the most consolidated, but runs on contested legal ground. Provider software carries the best economics in the sector (recurring revenue, lower acquisition cost, high switching costs) and is the clearest infrastructure play.
The largest segment by revenue share, at roughly 45%, and the most economically difficult. The unit-economics ceiling is most acute here, because acquisition cost exceeds the value of a single consultation, and the segment competes against the free public alternative of eSanjeevani. Survival depends on moving away from one-off acute consultation towards repeat use, specialty depth and business-to-business channels. The moat is clinical quality, specialty focus and brand, not price.
The largest segment by absolute revenue and the most consolidated, dominated by conglomerate-backed platforms. Margins are thin, 15–25%, so profitability depends on scale, private label, chronic-refill subscriptions and data. It carries the sector's single largest policy risk, since the governing rules have never been notified. The moat is scale and supply-chain depth.
Booking, home collection and digital reporting of tests: about 30% of revenue with e-pharmacy. Home sample collection is operationally complex and capital-intensive, which is where the moat sits: logistics, turnaround time, trust and accreditation. Contested by digital-native aggregators and by offline pathology chains moving online.
Electronic records, practice management and clinic platforms sold to providers (the best economics in the sector: recurring revenue, lower acquisition cost, high switching costs). Underbuilt relative to the opportunity, and ABDM is now creating fresh demand for compliant, interoperable systems. For many investors, the most defensible play.
Materially better unit economics than acute teleconsultation, because the relationship is recurring and retention is higher. Diabetes and cardiac programmes lead, combining coaching, monitoring and connected devices, which places the segment at the overlap with medtech. The moat is outcomes data and sustained engagement; reimbursement remains nascent.
Consumer wellness (fitness, nutrition, preventive health), a direct-to-consumer, brand-led segment of roughly 10% of revenue. Acquisition cost is high and churn is a constant risk, so the moat is brand, community and, in some cases, hardware.
The fastest-growing segment, expanding around 29% a year, and the most strategically important, because it is the wedge into the payer problem that constrains the rest of the sector. Group health lowers acquisition cost and brings recurring, employer-funded revenue. Regulated by IRDAI; consolidation has begun.
| ABDM metric | Figure (2026) |
|---|---|
| ABHA health-account IDs issued | 93 crore+ |
| Health records linked | 104 crore+ |
| Facilities registered | 5.47 lakh+ |
| ABDM-certified private firms | 1,000+ |
Source: PIB, 6 July 2026 (accounts and records) and 12 August 2026 (registries).
India's distinguishing asset in digital health is a government-built public infrastructure: a national health-identity and interoperability layer, and the world's largest government-led telemedicine service. One is free distribution; one is also a public competitor.
The Ayushman Bharat Digital Mission issues the ABHA identifier (a unique health ID that lets records move across providers) and sets the standards through which systems exchange data. As of July 2026 it had issued over 93 crore ABHA accounts and linked over 104 crore health records (PIB, 6 July 2026), and by August 2026 over 5.47 lakh facilities stood on the Health Facility Registry and over 10.50 lakh professionals on the Healthcare Professionals Registry (PIB, 12 August 2026). More than 1,000 private firms are ABDM-certified, a network effect that compounds with every participant.
Launched in 2019, eSanjeevani is the world's largest government-led telemedicine initiative. By 15 September 2026 it had delivered 50.01 crore teleconsultations across 36 states and union territories, with women accounting for 57.14 per cent of use (MoHFW, 6 October 2026), supported by roughly 220,000 providers and integrated with ABDM; more than 127,000 Health and Wellness Centres function as telemedicine hubs. For a private platform it is both a demonstration of latent demand and a free public alternative in basic consultation, which is precisely why private teleconsultation must compete on specialty, quality and convenience rather than price.
A venture can authenticate patients through ABHA, find providers through the registries, exchange records through the consent manager, and, through the Unified Health Interface (UHI), let a patient on any app discover and book any participating provider. UHI carries the potential to unbundle the closed platforms, turning discovery and booking into an open network rather than a walled garden. The network is still early, and building on government rails carries dependency on their pace.
Reconciled from Custom Market Insights, Mordor Intelligence and industry trackers. Ranges reflect genuine source disagreement on scope. Current to June 2026.
The market is large and fast-growing, but its defining economic feature is not its size. It is that the businesses within it are gated by unit economics rather than by capital or clinical approval.
| Measure | Figure (2025) | Note |
|---|---|---|
| Digital-health market size | ~$15–18B | $17.81B on a broad basis (Grand View Research, 2025); Custom Market Insights is materially lower at $8.79B (2024) |
| 2033 projection | $100B+ | ~$107B at ~25% CAGR (CMI) |
| Growth (CAGR) | ~20–25% | Varies by segment and scope |
| Telehealth sub-market | ~$3.9B (2025) → ~$9.8B (2030) | ~20% CAGR (Mordor) |
| Startup base | ~11,000 | ~90% pre-revenue or sub-₹1 cr revenue |
| 2025 funding | ~$0.70B / 54 deals | Fell from the ~$1.13B 2024 rebound (Inc42, 2026) |
Consider a direct-to-consumer teleconsultation venture with an acquisition cost of ₹1,200 and a first consultation priced at ₹500 at a 50% gross margin: a contribution of ₹250. That first transaction recovers only a fifth of the acquisition cost. To reach a healthy lifetime value of three to five times acquisition cost, the venture must generate ₹3,600–6,000 of contribution per user, roughly fourteen to twenty-four further consultations, or far fewer if each visit is bundled with a diagnostic test or pharmacy order at higher margin. The same user acquired through a corporate contract at ₹300, generating recurring annual revenue, repays within months.
| Model | CAC | Gross margin | Economic logic |
|---|---|---|---|
| D2C teleconsultation | ₹800–2,000+ | 40–60% | A single consult never repays CAC; viable only via repeat, cross-sell or high-ticket |
| E-pharmacy | Moderate; volume-led | 15–25% | Thin margins; profit through scale, private label, data; logistics-heavy |
| Platform (multi-segment) | Amortised across streams | Blended | One acquisition monetised across consult, pharmacy, diagnostics; 18–24 months to profit |
| B2B / corporate & SaaS | ₹150–500 per user | Recurring, sticky | Lower CAC, higher LTV, longer sales cycle; the most defensible economics |
Illustrative models, indicative only. Current to June 2026.
The unit-economics trap exists because India has no dominant payer for digital care, so the cost of acquisition falls on the venture rather than on an insurer. The escape route is the deepening of the payer base, and that base is now growing quickly.
Out-of-pocket spending dominates, at over 60% of health expenditure. AB PM-JAY is vast, at over 500 million beneficiaries, but underfunded and slow to reimburse. Corporate group health is growing but concentrated in the technology and finance sectors. Most ventures therefore depend on out-of-pocket or corporate revenue, which makes acquisition cost the decisive metric.
The shift now under way is in insurance. Health insurance became the largest segment of India's non-life market in FY25, at about 41% of gross premium, overtaking motor. The health-insurance market is estimated at roughly $16 billion in 2025 and projected to reach about $48.5 billion by 2035, a compound rate near 12%. The white spaces are precisely the ones that would relieve the digital-health problem: out-patient cover, mental-health cover, senior inclusion, rural penetration and prevention-led engagement.
| Payer pool | Scale & direction | Relevance to digital health |
|---|---|---|
| Out-of-pocket | 60%+ of health spend; the default today | The source of the CAC trap |
| Private health insurance | ~$16B (2025) → ~$48.5B (2035), ~12% CAGR | OPD & group cover is the escape route |
| Corporate group health | Growing; employer-funded | Lowest-CAC channel; the insurtech wedge |
| Government (PM-JAY) | 500M+ beneficiaries; teleconsult reimbursement emerging | Volume; slow and low reimbursement |
Sources: IRDAI; Mordor Intelligence and IMARC (2025); IRDAI senior-premium cap (January 2025). Current to June 2026.
As out-patient and group cover deepen, the sector's dependence on out-of-pocket payment eases and the route to sustainable unit economics opens. This is why health insurtech, the seventh segment, is strategically the most important: it is the wedge into the payer.
Sources: MoHFW; CDSCO; Delhi High Court direction (Nov 2023); DPDP Act 2023. Current to June 2026.
Digital health is governed by a patchwork of instruments rather than a single code. Some are clear; others (e-pharmacy above all) remain unsettled after years, and that ambiguity is itself a determinant of which models are financeable.
| Instrument | Scope | Status |
|---|---|---|
| Telemedicine Practice Guidelines 2020 | Who may practise; consent; prescriptions; records | In force; cross-state licensure friction remains |
| E-pharmacy draft rules | Online sale of medicines | Drafted Aug 2018; never notified; under court direction since 2023 |
| Drugs & Cosmetics Act 1940 / Rules 1945 | Dispensing, prescription, storage | In force; e-pharmacies comply with offline rules in the interim |
| Digital Personal Data Protection Act 2023 | Health-data consent, localisation, deletion | Enacted; penalties up to ₹250 crore |
| NABL / ISO 15189 | Diagnostic-lab accreditation | In force for labs |
| CDSCO: Software as a Medical Device | Clinical AI as a regulated device | AI diagnostic software is Class C; final guidance CDSCO/MD/GD/MDSW/01/2026, 21 July 2026, carries an Algorithm Change Protocol |
| IRDAI | Insurance distribution and claims | In force for insurtech |
The most consequential gap is e-pharmacy. Draft rules to amend the Drugs and Cosmetics Rules were issued in August 2018 but have never been notified. In November 2023 the Delhi High Court directed the central government to frame a policy within eight weeks, observing that the rules had been pending for over five years. In the interim, online pharmacies operate under the existing offline drug law. The effect is a large, consolidated segment running on contested legal ground: a standing risk to any e-pharmacy thesis, and a reason valuations there carry a regulatory discount.
Consolidation is the expected path: the winners expand horizontally into pharmacy, diagnostics and insurance, while undercapitalised single-segment players are acquired or exit. An estimated 20–30% of the base is likely to fail or be absorbed over the next two years. The sector has moved through four phases: foundation (2005–15), the telemedicine boom (2015–20), consolidation and the 2023 correction (2020–23),
and the present phase of profitability and defensibility (2024 onward).
Capital and revenue are concentrating. The top five firms control roughly 60% of revenue in teleconsultation and e-pharmacy; beneath them is a long, fragmented tail of some 11,000 startups, most pre-revenue.
| Company | Revenue (latest) | Focus | Status |
|---|---|---|---|
| PharmEasy (API Holdings) | ₹6,869 cr (FY26) | E-pharmacy, diagnostics | Private; IPO deferred; 2024 down round |
| Tata 1mg | ₹2,936 cr (FY26) | Integrated platform | Tata Digital-backed |
| HealthKart | ₹1,021 cr | Nutrition & wellness (D2C) | Profitable (₹38 cr PAT FY24) |
| Cult.fit | ₹927 cr | Fitness & wellness | Narrowing losses |
| MediBuddy | ₹645 cr (→ ₹743 cr FY25) | Corporate group health | Losses cut ~37% |
| Pristyn Care | ₹601 cr | Surgery-care platform | Valuation ~$1.17B (Nov 2025) |
| Healthians | ₹243 cr | E-diagnostics | EBITDA breakeven (FY24) |
| Practo | ₹240 cr | Discovery, teleconsult | Unicorn ($1.2–1.5B) |
Per company filings and Entrackr / Inc42 reporting (FY24, with FY25 where disclosed). Ranked by FY24 operating revenue. Current to June 2026.
Funding has rebounded from the 2023 correction, but it is disciplined: it rewards positive unit economics, platform breadth and a credible path to profit, and it has repriced the consumer-health businesses that scaled on growth alone.
Indian health-technology startups raised approximately $1.13 billion across 112 deals in 2024, with about $496 million across 38 rounds in the first quarter of 2025 alone. Roughly 30% of health-technology venture capital now flows to medtech and diagnostics rather than to pure teleconsultation, and undifferentiated direct-to-consumer brands have seen early-stage funding contract sharply. The repricing of the 2021 cohort is the defining feature of the cycle: PharmEasy raised its 2024 round at a steep discount to its peak, and Pristyn Care's valuation stood at about
$1.17 billion in November 2025, down some 17% from its $1.4 billion peak.
Digital health draws a broad capital base, but the most important actors are strategic: large domestic groups (Tata Digital, Reliance Retail, Apollo) are the defining acquirers and growth backers, and family offices such as Ranjan Pai's Manipal vehicle have stepped in to reprice and stabilise the larger platforms. The realistic exit, for now, is strategic acquisition or a private-equity secondary rather than a public listing.
| Landmark deal | Acquirer | Terms / significance |
|---|---|---|
| 1mg | Tata Digital | ~65% stake (2021); Tata's entry into integrated digital health |
| Netmeds | Reliance Retail | 60% for ₹620 cr; Reliance's e-pharmacy entry |
| Medlife | PharmEasy | All-stock (2021); created the largest online pharmacy |
| Thyrocare | PharmEasy | 66.1% for ₹4,546 cr (2021); e-pharmacy buys a listed diagnostics chain |
| RenewBuy | InsuranceDekho | ~₹7,400 cr merger (May 2025); the defining insurtech consolidation |
| PharmEasy | Ranjan Pai family office | ₹1,804 cr down round (2024); repricing of the e-pharmacy leader |
Sources: Business Standard, Inc42, Entrackr (2021–25); company disclosures. Current to June 2026.
The defining development of 2025–26 is the arrival of generative AI as a horizontal capability across every segment. Adoption has been rapid: the share of Indian clinicians using AI tools rose from about 12% in 2024 to 41% in 2025, surpassing the United States and the United Kingdom.
AI medical scribes: Eka Care's EkaScribe, built on its purpose-trained Parrotlet models, converts multilingual doctor–patient conversations into structured notes and prescriptions. Conversational triage: Sarvam AI deploys voice-enabled, multilingual agents that reach rural patients through WhatsApp and low-bandwidth interfaces. Health-reasoning models: Fractal's Vaidya 2.0 supports emergency assistance and symptom checking. Public-health AI: government deployments in tuberculosis and diabetic-retinopathy screening have been associated with a 27% decline in adverse TB outcomes.
India's distinctive advantage is frugal, sovereign AI: small, domain-specific models that cut inference costs by 60–97%, tuned for Indic languages and voice-first, low-bandwidth use. The significance is twofold. Generative AI lowers the cost to serve, and it attacks the binding doctor-supply constraint by extending scarce clinicians through triage, documentation and decision support.
Accuracy, governance, liability and the DPDP Act all apply, and these systems are positioned as decision support rather than autonomous diagnosis. Sources: EY; PIB; Digital Health News; Rest of World; company disclosures (2025–26).
Three verticals sit beneath the mainstream segments, underserved relative to need and growing quickly. Each cuts across the seven segments rather than replacing them, and each has begun to attract dedicated capital.
| Vertical | Signal | Representative players |
|---|---|---|
| Mental health | Stigma easing; corporate & insurer demand | Wysa (~$30M), Amaha (~₹100 cr, 2026), Lissun (~$5M) |
| Femtech / women's health | ~$310M (2025) → ~$3.87B (2030) | Soothe, Plackal (Maya), Gytree, Janitri |
| Elder care / geriatric | ~$3B silver economy; ageing & PM-JAY 70+ | Emoha, KITES, Primus, Pranyaas |
Sources: Inc42, Digital Health News, MyndStories; company disclosures and Tracxn; Frost & Sullivan. Current to June 2026.
Mental-health technology has moved from the margins to a fundable category. Wysa, a Bengaluru conversational-support platform, has raised about $30 million and reports more than five million users across 95 countries; Amaha raised about ₹100 crore in October 2026, including ₹10 crore of debt from Alteria Capital, at a post-money valuation near ₹350 crore. Women's-health technology is the most developed of the three, at roughly $310 million in 2025 and growing towards $3.87 billion by 2030, across a few hundred active companies. Elder care is earlier but structurally supported by an ageing population and the AB PM-JAY extension to citizens aged 70 and above; Emoha closed a Series B1 of about ₹85 crore in July 2026 and
announced the Shremoha senior-living joint venture on 2 July 2026.
The Indian opportunity is best read first against the global market, and then against the specific conditions that make India distinct.
Digital health is a large and fast-growing global market, led by the United States, where established reimbursement codes and a concentrated payer system underwrite telehealth and remote monitoring. The COVID-19 pandemic normalised remote care worldwide, advancing adoption by years within months. India is a comparatively small but among the fastest-growing parts of this market; its distinguishing features are the scale of unmet demand and a government-built public digital-health infrastructure of a kind few other markets possess.
That public infrastructure is the hinge. In the United States the payer solves monetisation and the constraint is cost; in China the conglomerate super-app builds a closed consumer loop; in India the state builds the rails and the private sector builds on top. The reach is cheaper and the monetisation is harder, and every later chapter is a variation on that theme.
An investor pricing Indian digital health against US or Chinese comparables misreads it. The unit economics, the payer structure and the distribution model are categorically different, and the businesses that travel are the ones built for India's public-rails reality, not imported from a payer-led market.
The builder thesis follows. A venture can authenticate patients through ABHA, find providers through the registries, exchange records through the consent manager, and, through UHI, let a patient on any application discover and book any participating provider. For founders, this lowers the cost of building distribution and trust, and it is the clearest route to interoperability. UHI in particular carries the potential to unbundle the closed platforms, since discovery and booking become an open network rather than a walled garden.
The caution is that the network is early. UHI adoption and its network effects are nascent, and building on government rails carries dependency on their pace and uneven maturity. The rails lower the cost of reach; they do not yet guarantee the demand.
Source: National Health Authority / ABDM; UHI documentation. Current to June 2026.
ABDM is best understood not as a registry of statistics but as a set of composable building blocks: an India Stack for health on which private applications build, rather than rebuilding identity, records and discovery for themselves.
| Block | Function |
|---|---|
| ABHA: health ID & address | A portable identity that ties a patient's records together across providers |
| HFR: Health Facility Registry | A national directory of hospitals, clinics, labs and pharmacies |
| HPR: Healthcare Professionals Registry | A verified directory of doctors and practitioners |
| HIE-CM: Consent Manager | Consent-driven exchange of records; the patient authorises each share |
| UHI: Unified Health Interface | An open network to discover, book, conduct and pay for services across any app: the UPI for health |
~45% of revenue · high CAC, low single-consult value · the hardest economics in the sector.
Teleconsultation is the largest segment by revenue share and the most economically difficult. Its sub-segments span general and specialty consultation, mental health, second opinions and tele-ICU. The unit-economics ceiling is most acute here, because acquisition cost exceeds the value of a single consultation, and the segment competes against a free public alternative in eSanjeevani.
Survival therefore depends on moving away from one-off acute consultation towards repeat use, specialty depth and business-to-business channels. The moat is clinical quality, specialty focus and brand, not price. The firms that endure are those that convert a consultation into a relationship (a chronic-care programme, a diagnostics order, a corporate contract) rather than a transaction.
Practo, Apollo 24|7, MediBuddy and Tata 1mg.
Largest by absolute revenue · thin margins (15–25%) · the sector's single largest policy risk.
E-pharmacy is the largest segment by absolute revenue and the most consolidated, dominated by
conglomerate-backed platforms. Margins are thin, so profitability depends on scale, private label, chronic-refill subscriptions and data, and the business is logistics-heavy.
It also carries the sector's single largest policy risk, since the governing rules have never been notified. A large, consolidated segment runs on contested legal ground, and that ambiguity sits as a discount on every e-pharmacy valuation. The moat is scale and supply-chain depth.
PharmEasy, Tata 1mg, Netmeds (Reliance) and Apollo Pharmacy.
~30% with e-pharmacy · capital-intensive home collection · logistics and trust the moat.
E-diagnostics (booking, home collection and digital reporting of tests) accounts, with e-pharmacy, for about 30% of revenue. Home sample collection is operationally complex and capital-intensive, which is where the moat sits: logistics, turnaround time, trust and accreditation.
The segment is contested by digital-native aggregators and by the established offline pathology chains moving online. Accreditation under NABL or ISO 15189 is the credibility floor; logistics and turnaround are the differentiation above it.
Tata 1mg Labs, Redcliffe, Orange Health and Healthians, against incumbents such as Dr Lal and Metropolis.
Recurring SaaS · lower CAC, high switching cost · the best economics in the sector.
Provider software (electronic records, practice management and clinic platforms sold to hospitals, clinics and doctors) carries the best economics in the sector: recurring revenue, lower acquisition cost and high switching costs.
It is also underbuilt relative to the opportunity, and ABDM is now creating fresh demand for compliant, interoperable systems. The moat is switching cost and the data that accrues. This is the clearest infrastructure play and, for many investors, the most defensible position in Indian digital health.
Eka Care, HealthPlix, Halemind, Practo Ray and Bajaj Finserv Health.
Better economics than acute teleconsultation · recurring, higher LTV · the medtech overlap.
Chronic-care management offers materially better unit economics than acute teleconsultation, because the relationship is recurring and retention is higher. Diabetes and cardiac programmes lead, combining coaching, monitoring and, increasingly, connected devices, which places the segment at the overlap with medtech.
The moat is outcomes data and sustained engagement; reimbursement remains nascent but is the upside. As OPD and chronic-disease cover deepen, this segment is among the best positioned to convert engagement into a paid, recurring relationship.
BeatO and Fitterfly in diabetes, with Phable and Wellthy across conditions.
~10% of revenue · D2C, high CAC, brand-led · the most debated as core health.
Consumer wellness (fitness, nutrition and preventive health) is a direct-to-consumer, brand-led segment, and the one whose classification as core health is most debated. Acquisition cost is high and churn is a constant risk, so the moat is brand, community and, in some cases, hardware.
It is treated here as an adjacent consumer segment rather than clinical care. The winners differentiate on brand and, increasingly, on a hardware hook: the wearable that turns a subscription into a habit.
HealthifyMe, Cult.fit and Ultrahuman, the last differentiated by its wearable.
Fastest-growing (~29% CAGR) · IRDAI-regulated · the wedge into the payer.
Health insurtech is the fastest-growing segment and the most strategically important, because it is the wedge into the payer problem that constrains the rest of the sector. Group health lowers acquisition cost and brings recurring, employer-funded revenue; claims technology and benefits administration are the other entry points.
It is regulated by IRDAI and has begun to consolidate, with the RenewBuy–InsuranceDekho merger the defining transaction. The moat is distribution, employer relationships and claims technology: the assets that put an insurer, not the patient, on the other side of the transaction.
Onsurity, Plum, Nova Benefits, Even Healthcare and Policybazaar.
The top five firms control roughly 60% of revenue in teleconsultation and e-pharmacy. Beneath them is a long, fragmented tail of some 11,000 startups, most pre-revenue.
Consolidation is the expected path: the winners expand horizontally into pharmacy, diagnostics and insurance, while undercapitalised single-segment players are acquired or exit. An estimated 20–30% of the base is likely to fail or be absorbed over the next two years.
| Phase | Period | Defining development |
|---|---|---|
| 1 · Foundation | 2005–2015 | Practo founded (2008); doctor discovery; hospital and lab software |
| 2 · Telemedicine boom | 2015–2020 | Telemedicine Guidelines (2020); COVID advances adoption by a decade in months |
| 3 · Consolidation | 2020–2023 | Horizontal integration; SoftBank, Tiger, Accel flood capital; 2023 correction exposes unit economics |
| 4 · Profitability & defensibility | 2024–present | Capital discipline returns; reimbursement begins to unlock; consolidation accelerates |
Evolution of the sector. Current to June 2026.
The sector now sits firmly in the fourth phase. The land grab is over; the defensibility contest has begun, and it is won on unit economics, breadth and the data that accrues from owning the patient relationship across segments.
Digital health draws a broader, more conventional capital base than medtech, because it carries software rather than hardware risk. The defining force, however, is strategic.
| Investor type | Representative names | Focus |
|---|---|---|
| Healthcare-focused VC | HealthQuad, W Health Ventures, 3one4, Kae Capital | Health-specific early and growth |
| Generalist early-stage VC | Peak XV, Accel, Lightspeed, Elevation, Nexus | Series A–C across segments |
| Crossover / late-stage | Tiger Global, SoftBank | Large, later rounds in the 2021 cycle |
| Sovereign / global PE | Temasek, GIC, Prosus, General Atlantic, TPG Growth | Scale platforms; e-pharmacy and diagnostics |
| Strategic / corporate | Tata Digital, Reliance Retail, Apollo | Acquisition, distribution and stabilisation |
| Family offices | Ranjan Pai (Manipal / MEMG), Premji Invest | Repricing and stabilising the larger platforms |
Illustrative of where each tends to play. Current to June 2026.
Large domestic groups are the most important acquirers and growth backers, and family offices have stepped in to reprice and stabilise the larger platforms. The realistic exit, for now, is a strategic acquisition or a private-equity secondary rather than a public listing, a fact that shapes how founders should build and how investors should underwrite.
The capital map is conventional, but the bar at each stage has risen: every round now screens for unit economics, not just growth.
| Stage | Typical size | Criteria | Timeline |
|---|---|---|---|
| Seed / Pre-Seed | ₹1–5 cr | Problem validation; founding team; early traction | 6–12 months |
| Series A | ₹10–30 cr | Product-market fit; unit-economics proof | 12–18 months |
| Series B | ₹50–150 cr | Clear path to profitability; competitive moat | 18–24 months |
| Series C+ | ₹200 cr+ | Profitability or a credible timeline; market leadership | 24+ months |
Indicative stage map. Current to June 2026.
Unit-economics insight: a calculated CAC, LTV and payback, and a credible path to profit. Traction: active users, retention and repeat rate showing genuine resonance. Regulatory clarity: compliance, licensing and policy risk thought through, with no surprises. An unfair advantage: proprietary data, clinical partnerships, distribution or IP competitors cannot replicate.
Most digital-health ventures fail not between prototype and approval, as in medtech, but between user acquisition and sustainable revenue.
The failures are instructive. HealthcareMagic could not monetise; scarce high-quality doctors and low-cost consultations could not support the economics. Medwell Ventures was capital-intensive in labs and centres without sustainable collections. A broad cohort of direct-to-consumer health brands failed at a rate near 80%, competing on price until margins disappeared. In each case acquisition cost exceeded lifetime value at scale.
The survivors share four moves. The platform model (Tata 1mg, PharmEasy) owns teleconsultation, pharmacy and diagnostics, so one acquired customer is monetised across several transactions. The business-to-business channel (MediBuddy) sells corporate group health at lower acquisition cost and higher retention. Niche, high-ticket segments such as chronic care, fertility and surgery carry higher fees and more repeat visits. And the infrastructure play sells to hospitals and clinics rather than end users, with lower acquisition cost and recurring revenue.
Indicative go-to-market economics. Current to June 2026.
The market splits along a structural line, and the winning model is hybrid: high-margin urban operations subsidise rural expansion through public channels.
Urban tier-1 markets account for over 70% of platform revenue, with users willing to pay ₹500–1,500 a consultation, but they are saturated and commoditised, and competition is on price and convenience. The opportunity there is specialisation: mental health, fertility, dermatology, and premium positioning. Rural and tier-2 and tier-3 markets carry the larger supply gap, since 70% of specialists serve the urban third, but they face infrastructure barriers and limited willingness to pay, and the government scheme is the primary channel.
| Channel | When it fits | Economics |
|---|---|---|
| Direct-to-consumer | Differentiated or premium specialty care | High CAC (₹1,000–2,500); viable only on high-ticket or add-on monetisation |
| Business-to-business | Employee wellness; hospital and clinic software | Lower CAC (₹200–500), higher LTV; 3–6 month sales cycle |
| Government & public health | Rural and underserved populations | Massive volume; slow (90+ day) and low (₹50–200) reimbursement |
| Platform / marketplace | Aggregating services to cross-sell | CAC amortised; 18–24 months to profit; capital-heavy |
The platform plays show how owning multiple segments rescues unit economics; eSanjeevani shows the size of the latent demand, and the public competitor private players must out-specialise.
The two leading platforms illustrate the same solution: own several segments so that one acquired customer is monetised across many transactions. Tata 1mg combines teleconsultation, e-pharmacy and diagnostics under Tata Digital, reaching ₹2,936 crore of revenue in FY26, up 23 per cent on FY25 (Entrackr, 2026). PharmEasy, through API Holdings, built the largest online pharmacy (extended by the all-stock acquisition of Medlife) and reported consolidated revenue near ₹6,869 crore in FY26, up about 14 per cent on FY25 (UnlistedZone, 2026), after a 2024 down round repriced the business. Both show that scale and breadth, not a single high-margin product, are the route to viability, and both show its cost: the capital required to build network effects is large, and the path to profit runs to several years.
As the Government's national telemedicine service, eSanjeevani has delivered over 50 crore teleconsultations since 2019, free at the point of use. Its scale proves that demand for remote consultation is real and vast. For a private platform the implication is precise: the basic-consultation segment is occupied by a free public alternative, so private teleconsultation must compete on specialty depth, clinical quality, convenience and outcomes rather than price.
Five buyer pools determine whose economics work. The whole sector is a contest to move revenue from the most expensive pool to the cheapest.
| Buyer pool | Character | Implication |
|---|---|---|
| Consumers (out-of-pocket) | Over 60% of health spend; dominant for D2C | High CAC; price-sensitive; needs repeat or high-ticket |
| Corporates (group health) | Employers buying employee wellness | Lower CAC, higher LTV; concentrated in IT/finance |
| Hospitals & clinics | Buyers of provider SaaS and white-label teleconsult | Recurring revenue; sticky; lower CAC |
| Insurers (private & insurtech) | Coverage expanding; OPD and wellness add-ons | Reimbursement growing slowly; premium plans first |
| Government (PM-JAY, eSanjeevani) | 500M+ beneficiaries; massive volume | Slow, low reimbursement; demands capital efficiency |
The five buyer pools. Current to June 2026.
The strategic instruction is the same one the whole edition returns to: a business that depends on the out-of-pocket consumer carries the highest acquisition cost in the sector, while a business that earns the corporate, provider or insurer relationship carries the lowest. The migration from the first pool to the others is the work of 2027.
Four areas stand out as the next layer of opportunity, and each maps to a distinct technology and a distinct defensibility.
ABDM-native services built on the ABHA identity and the government health stack: a new layer with low duplication and inherited distribution. AI-powered diagnostics: a heavy validation and regulatory burden, but in return high defensibility and an export angle. Chronic-care management: materially better unit economics than acute teleconsultation, through recurring engagement. Healthcare logistics: last-mile delivery
and cold chain, capital-intensive but high-margin where solved.
| Segment | Core technology | Key consideration |
|---|---|---|
| Teleconsultation | Video, scheduling, payments | ABDM interoperability; data localisation |
| E-pharmacy | Order management, logistics, prescription verification | Cold chain; drug-category compliance |
| Diagnostics | Collection scheduling, lab and report systems | Accuracy; NABL / ISO 15189 accreditation |
| Clinical AI | ML on imaging, ECG, pathology | Clinical validation; CDSCO approval |
| Health records / SaaS | EHR; ABDM-compliant exchange | Interoperability standards; governance |
Indicative technology map by segment. Current to June 2026.
India's payer landscape is fragmented, and that is the root of the unit-economics problem. Four models describe how ventures actually make the numbers work.
Unlike the United States, where Medicare and Medicaid are clear payers, India has no dominant payer for digital care. Out-of-pocket spending dominates at over 60% of health expenditure; AB PM-JAY is vast at over 500 million beneficiaries but underfunded and slow; corporate group health is growing but concentrated; private insurance covers teleconsultation only in premium plans. Most ventures therefore depend on out-of-pocket or corporate revenue, which makes acquisition cost the decisive metric.
| Model | CAC | Margin | Economic logic |
|---|---|---|---|
| D2C teleconsultation | ₹800–2,000+ | 40–60% | A single consult never repays CAC; viable only via repeat, cross-sell or high-ticket specialty |
| E-pharmacy | Moderate; volume-led | 15–25% | Thin margins; profitability through scale, private label and data |
| Platform (multi-segment) | Amortised | Blended | One acquisition monetised across consult, pharmacy and diagnostics |
| B2B / corporate & SaaS | ₹150–500 per user | Recurring | Lower CAC, higher LTV; the most defensible economics |
Illustrative; indicative only. Current to June 2026.
The route to sustainable unit economics runs through the payer. As out-patient and group cover deepen, the sector's dependence on out-of-pocket payment eases, which is why the insurance market, growing
from ~$16B toward ~$48.5B by 2035, is the single most important external variable for digital health.
Mental-health technology has moved from the margins to a fundable category, as stigma eases and corporate and insurer demand grows.
The category now attracts dedicated capital and reports genuine scale. Wysa, a Bengaluru-based conversational-support platform, has raised about $30 million from Google, pi Ventures and Kae Capital, and reports more than five million users across 95 countries. Amaha, formerly InnerHour, raised about ₹100 crore in October 2026 at a post-money valuation near ₹350 crore, on FY25 revenue of ₹27.57 crore. Lissun raised about $2.5 million led by RPSG Capital Ventures.
The economics are improving because the buyer is shifting. Corporate employee-assistance contracts and insurer wellness add-ons move mental health off the high-acquisition-cost direct-to-consumer model and onto the recurring, employer-funded channel that the rest of the sector is also chasing. Mental health is, in that sense, a leading indicator of the payer migration the whole edition describes.
Two further verticals sit beneath the mainstream, each structurally supported by demography and each beginning to attract dedicated capital.
Women's-health technology is the most developed of the underserved verticals, at roughly $310 million in 2025 and growing towards $3.87 billion by 2030, with a few hundred active companies. The category spans fertility, maternal health, menstrual health and gynaecological care, and its defensibility rests on clinical credibility and sustained engagement rather than on one-off transactions. Representative players include Soothe, Plackal (Maya), Gytree and Janitri.
Elder care is earlier but structurally supported by an ageing population and the AB PM-JAY extension to citizens aged 70 and above; India's silver economy is estimated near $3 billion. Emoha closed a Series B1 of about ₹85 crore in July 2026; KITES focuses on geriatric, dementia and palliative care; and Primus raised a ₹65-crore Series A led by the Manipal (Ranjan Pai) family office. The model combines care coordination, remote monitoring and at-home services: a chronic-care relationship by another name, with the same recurring-revenue advantage.
Deal activity has two faces: strategic consolidation, which provides the exits, and venture rounds, which provide the entry. In digital health the consolidation side is unusually developed: domestic conglomerates acquiring the segment leaders.
| Target | Acquirer | Terms / significance |
|---|---|---|
| 1mg | Tata Digital | ~65% stake (2021); Tata's entry into integrated digital health |
| Netmeds | Reliance Retail | 60% for ₹620 cr (~$83M); Reliance's e-pharmacy entry |
| Medlife | PharmEasy (API Holdings) | All-stock (2021); created the largest online pharmacy |
| Thyrocare | PharmEasy (API Holdings) | 66.1% for ₹4,546 cr (2021); e-pharmacy buys a listed diagnostics chain |
| Aknamed | API Holdings | Acquisition (2021); hospital and specialty supply-chain |
| Karkinos Healthcare | Reliance | Strategic investment (2024); distributed cancer care |
| RenewBuy | InsuranceDekho | ~₹7,400 cr merger (May 2025); the defining insurtech consolidation |
| PharmEasy | Ranjan Pai family office | ₹1,804 cr down round (2024); repricing of the e-pharmacy leader |
Sources: Business Standard, Inc42, Entrackr (2021–25); company disclosures. Current to June 2026.
The pattern is unambiguous: the conglomerates (Tata, Reliance and the Manipal group) are the defining acquirers, and the segment leaders are the targets. For a founder, this shapes the endgame; for an investor, it defines the realistic exit.
Sources: Tracxn, Crunchbase, PitchBook and company filings (2024–26). Some figures cumulative. Current to June 2026.
The funding standings show where capital has concentrated, and the IPO question frames the only exit the sector has not yet proven.
| Company | Funding / standing | Focus |
|---|---|---|
| PharmEasy (API Holdings) | ~$1.1B total; ₹1,804 cr down round (2024); FY26 revenue ₹6,869 cr | E-pharmacy & diagnostics |
| Tata 1mg | ~$240M raised; FY26 revenue ₹2,936 cr | Integrated platform |
| Practo | ~$251M total; unicorn | Discovery & teleconsultation |
| Pristyn Care | ~$187M total; valuation ~$1.17B (Nov 2025, down from $1.4B) | Surgery-care platform |
| Eka Care | ~$19.5M total | ABDM-native records & provider SaaS |
| Onsurity | Growth-funded | Health insurtech (group) |
The realistic exit, for now, is strategic acquisition or a private-equity secondary rather than a public listing. PharmEasy's parent, API Holdings, filed for an initial public offering of up to ₹6,250 crore but withdrew it amid the 2022–23 correction; a revived listing is expected conditional on the business turning cash-flow positive, with several observers pointing to late 2026 at the earliest. The public market gates entry on demonstrated profitability (the same test that governs the private rounds), so the likeliest first listings are the platforms and insurtech-adjacent businesses that reach profit first.
The state of the sector · Volge Quarterly 2027
Six through-lines cut across the segments. Each is a force that will move the sector in 2027, and together they explain the Calls that follow.
Force 01 · Unit economics
A ₹800–2,000 acquisition against a ₹300–800 consultation was a subsidy, not a model. For most of the last decade, Indian digital health funded that subsidy with venture capital, and the headline growth it
bought was real but rented. In 2027 the rent comes due: the capital that once paid for acquisition now screens for the economics that make acquisition repay itself.
The escape is arithmetic, not ambition. A business survives only if lifetime value clears acquisition cost by a wide margin, and there are three honest ways to get there: repeat use, cross-sell into higher-margin pharmacy and diagnostics, or a move to channels where acquisition is structurally cheaper. The platforms that own multiple segments amortise the cost of a customer across years of transactions; the single-service app cannot, and the market has stopped pretending otherwise.
The failures are instructive. A broad cohort of direct-to-consumer health brands failed at a rate near 80%, competing on price until margins disappeared. In each case the cause was identical: acquisition cost exceeded lifetime value at scale, and no amount of growth closed the gap. 2027 is the year that lesson is fully priced in.
Force 02 · Channels
The winning channels in 2027 bypass paid acquisition entirely. Corporate group health arrives through the employer; government volume arrives through PM-JAY and eSanjeevani; and a venture built on the ABDM public rails reaches patients through infrastructure it did not have to buy. The consumer app that must purchase each user one advertisement at a time is structurally short against a competitor whose users arrive for free.
This is the practical meaning of India's public-rails model. The government built the identity, the registries and the consent layer; the firm that builds on them inherits distribution and trust at a fraction of the cost of manufacturing its own. More than 127,000 Health and Wellness Centres now function as telemedicine hubs, extending the public channel into rural India, and AB PM-JAY has begun to reimburse teleconsultation in select states.
The revenue mix is the tell. As public-rail and business-to-business channels carry the majority of net new growth, the economics of the sector quietly invert: the cheapest patient is the one the business never paid to acquire, and the firms organised around that fact outlast the ones organised around the app store.
Force 03 · Trust
The Digital Personal Data Protection Act turns health data from an asset to be hoarded into a liability to be governed, and, for the firms that govern it well, back into a moat. As the most sensitive category under the Act, health data is where compliance stops being overhead and starts being a price of entry.
The advantage accrues unevenly. A platform that can prove lawful, permissioned, consent-managed data wins the enterprise and government contracts that a less disciplined competitor cannot touch, because those buyers cannot afford the regulatory exposure of a careless vendor. Penalties of up to ₹250 crore concentrate the mind, and the ABDM consent architecture gives the compliant a standard to build to.
What looks like a burden in 2026 reads, by the end of 2027, as a competitive asset, and the gate through which the largest deals pass. The firms that treat data governance as a feature, not a tax, find that it sells.
Force 04 · The payer
Every unit-economics problem in Indian digital health traces back to one structural fact: there is no dominant payer for digital care, so the cost of reaching a patient falls on the venture rather than on an insurer. The most consequential development of 2027 is that the payer base is finally deepening.
Health insurance became the largest segment of India's non-life market in FY25, at about 41% of gross premium, and is projected to roughly triple by 2035. The white spaces (out-patient cover, mental-health cover, senior inclusion, prevention-led engagement)
are precisely the ones that would relieve the digital-health problem. Group cover, employer-funded and recurring, is the lowest-acquisition-cost channel in the sector.
This is why health insurtech, the seventh segment, is strategically the most important of the seven: it is the wedge into the payer, and the businesses that own the employer relationship and the claims rail are buying the thing every other segment lacks: someone other than the patient to pay.
Force 05 · Value migration
The value in Indian digital health is migrating away from the crowded front door of acute teleconsultation and towards the segments where the relationship recurs. Chronic-care management (diabetes, cardiac, adherence) carries materially better unit economics because retention is higher and the engagement is continuous. Provider software carries the best economics of all: recurring revenue, lower acquisition cost, high switching costs.
The direction of travel is consistent with where capital now flows. Roughly 30% of health-technology venture capital has rotated towards medtech, diagnostics and the recurring-revenue segments, and away from pure teleconsultation. The infrastructure play (selling to hospitals and clinics rather than to end users) is, for many investors, the most defensible position in the sector.
The implication for 2027 is that the league table reorders. The businesses that looked least glamorous in the consumer-app era (the EHR vendor, the chronic-care programme, the claims platform) are the ones whose economics survive contact with a disciplined market.
Force 06 · Frugal AI
India's edge here is frugality. Small, domain-specific, Indic-language models cut inference costs by 60–97% and run voice-first on low bandwidth, which matches the actual conditions of Indian care delivery. Adoption has been fast: the share of clinicians using AI tools rose from about 12% in 2024 to 41% in 2025, and the AI
scribe (EkaScribe and its peers) is on its way to becoming table stakes for any platform at scale.
The one constraint Indian digital health cannot engineer around is the supply of doctors: about 1.1 per 1,000 people, concentrated in the cities. Generative AI is the first technology that attacks that constraint directly, by extending each scarce clinician through triage, documentation and decision support rather than by adding clinicians the system does not have.
The caveats are real: accuracy, liability and the DPDP Act all bind, and these systems are decision support, not autonomous diagnosis. But read correctly, frugal AI is the accelerant across all seven segments, and it is strongest exactly where the sector is weakest: at the point where the cost to serve meets the shortage of people to serve.
The forces · Volge Quarterly 2027
The Act was assented on 11 August 2023 and then lay dormant, with no provision commenced until November 2025. The operative instrument is the Digital Personal Data Protection Rules 2025, notified as G.S.R. 846(E) by the Ministry of Electronics and Information Technology with a gazette date of 13 November 2025; the 14 November 2025 date that circulates in commentary is the day the file was uploaded, not the date of notification. A corrigendum, G.S.R. 892(E), followed on 10 December 2025. Commencement is phased. The Board provisions took effect on 13 November 2025, consent manager registration under Rule 4 and the First Schedule opens on 13 November 2026, and the substantive obligations follow eighteen months after that.
What commences on 13 May 2027 is the whole compliance burden: notice, consent, security safeguards, breach reporting, retention limits, data principal rights, children's data and Significant Data Fiduciary duties. Two provisions are operationally heavy. Rule 6 requires encryption or masking, access control, logging, backups and the retention of logs for one year. Rule 7
requires that a breach be intimated to each affected data principal and to the Board without delay, with a detailed report within seventy-two hours, and it sets no materiality threshold: the loss of one record is reportable on the same terms as the loss of one lakh.
What actually binds and when, where registration outruns adoption, who is in fact profitable, what a buyer pays, and three numbers in wide circulation that do not survive checking.
One Indian digital health obligation carries a firm date and a consequence: 13 May 2027. Everything else in the field is recommendatory, held in abeyance, confined to adopting states, or undated.
The single binding obligation facing an Indian healthcare provider in this window commences on 13 May 2027, when the substantive duties under the Digital Personal Data Protection Rules 2025 take effect. They bind every hospital, diagnostics operator, pharmacy chain, insurer and third-party administrator as a Data Fiduciary, and there is no sectoral carve-out for healthcare. The instruments more often discussed in board papers carry no commencement date at all, because they impose no obligation from which a date could run. The distinction is commercial: a recommendatory standard can be sequenced at the buyer's convenience, and a gazette-dated obligation cannot.
Significant Data Fiduciary status is a designation made by the Centre under section 10, and no entity has been notified as one. The duties that would follow, under Rule 13, are an annual data protection impact assessment, an annual audit, an India-based data protection officer and algorithmic due diligence. On children's data, Rule 12 read with the Fourth Schedule names clinical establishments and healthcare professionals among the exempt classes, but the scope of that exemption is contested, and a blanket hospital exemption should not be assumed.
The penalty figures are taken from the Schedule to the Act as relayed by secondary sources and have not been read from the gazette: up to Rs 250 crore for a security failure, Rs 200 crore for a breach-notification failure, Rs 200 crore on children's data, Rs 150 crore for Significant Data Fiduciary duties and Rs 50 crore residual. No DPDP penalty has been imposed on any entity.
Teleconsultation remains governed by the Telemedicine Practice Guidelines of 25 March 2020, issued by the Board of Governors in supersession of the Medical
Council of India as Appendix 5 to the IMC (Professional Conduct) Regulations 2002, and not rescinded. The National Medical Commission's Registered Medical Practitioner (Professional Conduct) Regulations 2023, notified on 2 August 2023, were held in abeyance by an Ethics and Medical Registration Board notice of 23 August 2023; no evidence has been found that the abeyance was lifted, and no successor was issued between 2024 and 2026. The regime in force is therefore older than vendor literature implies.
The only hard digital-record obligation on Indian providers sits in Rule 9(iv) of the Clinical Establishments Central Rules 2012, which requires an establishment to maintain and provide an electronic medical or health record for every patient. The parent Act of 2010 has been adopted in 19 states and union territories, and in all union territories except Delhi, as recorded on clinicalestablishments.mohfw.gov.in on a page last updated 30 October 2026; Karnataka and Kerala operate separate regimes. The obligation bites only in adopting states, and the penalty under section 40 runs to Rs 10,000 for a first contravention, Rs 50,000 for a second and Rs 5 lakh thereafter. The EHR Standards for India, revised in December 2016, were issued as recommendations states were advised to adopt, and so are recommendatory in substance.
Device and software licensing is the one area with settled dates behind it. The Medical Devices Rules 2017, G.S.R. 78(E) of 31 January 2017, came into force on 1 January 2018; licensing applied from 1 October 2022 for Class A and B devices and 1 October 2023 for Class C and D, following the notification of 11 February 2020 that brought all devices within the drug definition. The CDSCO Guidance Document on Medical Device Software, finalised 21 July 2026 as Doc No. CDSCO/MD/GD/MDSW/01/2026, collapses the software-as-a-medical-device split into one category and permits an Algorithm Change Protocol, but it is guidance and not binding.
| Instrument | Status today | Date |
|---|---|---|
| DPDP Rules 2025, substantive obligations | Binding on every Data Fiduciary, not yet commenced | 13 May 2027 |
| DPDP Rules 2025, consent manager registration | Binding on consent managers only | 13 November 2026 |
| Clinical Establishments Central Rules, Rule 9(iv) | Binding, adopting states only | In force |
| Instrument | Status today | Date |
|---|---|---|
| Telemedicine Practice Guidelines | In force, not rescinded | 25 March 2020 |
| NMC Professional Conduct Regulations 2023 | Held in abeyance | 23 August 2023 |
| EHR Standards for India, revised version | Recommendatory, states advised to adopt | December 2016 |
| CDSCO Medical Device Software guidance | Guidance, not binding | 21 July 2026 |
| IRDAI health master circular | Operative, no successor located | 29 May 2024 |
| ABDM participation | Voluntary, no statutory basis | No date published |
| NHCX onboarding | No mandate located | No date published |
What follows is a planning window, not a queue of deadlines. Before 13 May 2027 a provider has to complete work that cannot be bought in a quarter: a record of every processing flow and the lawful basis for it; consent notices that work at registration, admission and discharge rather than on a website; encryption, access control and logging to Rule 6, with one year of log retention; a breach drill tested against a seventy-two hour report and an intimation duty with no threshold; retention schedules that survive medico-legal practice; and a decision on whether contracted processors, the hospital system vendor and the third-party administrator among them, are bound to the same terms. None of that work depends on the digital mission, and none of it should wait on a mandate that has not been published.
Of 5.33 lakh facilities registered on the Ayushman Bharat Digital Mission, 2.72 lakh are using mission-enabled software. The gap, and not the growth, is the operating fact for anyone planning around the mission.
The most useful published number in Indian digital health is a ratio, and it is close to one half. At the third ABDM Mission Steering Group meeting of 10 July 2026, chaired by the Union Health Minister, the mission reported 5.33 lakh health facilities on the Health Facility Registry, of which 2.72 lakh were using ABDM-enabled software: 51 per cent. The same meeting reported 93.95 crore ABHA numbers, 105 crore linked health records and 9.85 lakh professionals on the Healthcare Professionals Registry. That is the only official registered-against-enabled split available, and it is the number a buyer should carry. Registration is free, voluntary and takes minutes; using enabled software is a procurement decision; and neither is the same as transacting, which is not published at all.
A method note that should be read before any ABDM figure is quoted. The mission's live dashboard at dashboard.abdm.gov.in is a client-side JavaScript application and cannot be read by a simple fetch, while abdm.gov.in serves a stale cached homepage still showing 14,15,49,620 Health IDs as on 03/12/2021. Every figure in this chapter therefore comes from a dated government release, a ministry statement, or reporting that cites the dashboard on a named date, and the provenance is given each time.
A tracker page dated 25 September 2026 gives more than 5.6 lakh facilities and about 11 lakh professionals while leaving the software-enabled count at 2.72 lakh. If that reading is accurate, registrations grew through the third quarter of 2026 while the enabled count stood still, and the ratio fell below 51 per cent. It is a single secondary source and not official, but it is consistent with the structure of the programme: registration is promoted, software replacement is not.
The 51 per cent figure is in any event an upper bound. Health Facility Registry fields, including whether a facility uses ABDM-compliant software, are self-declared and are not independently verified. One published verification rate stands against that: Karnataka is recorded at 93.9 per cent registry verification, which also shows verification to be a state effort rather than a national one.
The clearest account of why the ratio stalls is a peer-reviewed one. Kommuru and Agarwal, writing in Health Management Policy and Innovation 11(2) on 9 July 2026 from the Stanford Graduate School of Business, combined dashboard data with 15 interviews conducted between January and March 2026. Their finding is that milestone one, the creation of ABHA identifiers, has achieved mass scale, while milestone three, the one that would make the mission genuinely valuable for care coordination, remains extremely low. They give no number for it, because the National Health Authority publishes no milestone three figure. That absence is itself the most significant gap in the public record on Indian health data exchange.
The same paper locates the steepest drop-off between milestone two and milestone three, and attributes it to consent friction rather than technology. Patients miss the notifications on which retrieval depends, and in public hospitals where diagnostics are free, clinicians were reported to find it more expedient to reorder a test than to navigate the retrieval workflow. That is an economic finding rather than a technical one, and any business case resting on avoided duplicate testing has to answer it.
Rajasthan illustrates the gap in a single state. The state's integrated hospital management system auto-enrols an ABHA at the front desk, which produces
identifier volume without effort, yet the reported ABHA-to-electronic-record linkage rate is below 20 per cent. A second illustration comes from the Centre's own newest product: eSushrut@Clinic, built by C-DAC and launched in June 2026, had more than 2,200 facilities onboarded and had generated just over 1,633 health records, according to the government backgrounder of 6 July 2026. That is under one record per onboarded facility, and it is a cleaner adoption datapoint than any dashboard total.
The denominator deserves the same scepticism as the numerator. The Stanford paper records that CoWIN seeded roughly 130 million accounts without explicit separate consent, and that a re-application anomaly produces duplicates, with the consequence that the true denominator of unique active patients is significantly lower than headline counts imply. The count of integrated private solutions is also unsettled: more than 450 in July 2026 reporting, against more than 1,000 in the same journal in May 2026, with neither figure traceable to a named authority document.
| Measure, 10 July 2026 unless stated | Figure |
|---|---|
| Facilities on the Health Facility Registry | 5.33 lakh |
| Of which using ABDM-enabled software | 2.72 lakh, 51 per cent |
| ABHA numbers issued | 93.95 crore |
| Linked health records | 105 crore |
| Professionals on the Healthcare Professionals Registry | 9.85 lakh |
| Scan and Register tokens | About 24 crore |
| eSushrut@Clinic records, 2,200+ facilities, 18 June 2026 | 1,633 |
| Published milestone three volume | None |
Linked records are also concentrated: in July 2026 Uttar Pradesh accounted for 15.03 crore, Andhra Pradesh 11.95 crore, Bihar 7.37 crore, Rajasthan 6.32 crore and Gujarat 4.77 crore. A national total above a billion therefore describes a handful of large public systems rather than a uniform capability.
Later dashboard readings relayed by secondary sources give 96.43 crore ABHA and more than 110 crore records on 12 August 2026, 97.61 crore and 119.95 crore on 17 September 2026, and 98.71 crore and 126 crore on 27 October 2026. None is a primary citation. It should also be noted that there is a CAG performance audit of AB-PMJAY but none of ABDM, and that the Parliamentary Standing Committee's 144th Report of March 2023 criticised PM-ABHIM, not ABDM, for spending about 20 per cent of budget estimates.
The takeaway is a change in the diligence question. Whether a facility is registered tells a buyer almost nothing, because registration is costless and self-declared. The questions that carry information are whether its software is certified at milestones two and three, what proportion of discharges produce a linked record, and what proportion of consent requests are answered. None is published nationally, and the reason matters: the National Health Authority is, in the words of the Stanford paper, a convening and implementation body and not a regulator. That paper's recommendation follows, namely replacing payment per ABHA created with payment for milestone two and three volume. Until something of that kind happens, 2.72 lakh is the ceiling on what can be relied upon.
There is no primary source for Indian health-tech funding. Every figure in circulation originates with a commercial tracker, and the trackers disagree with each other and with themselves, in one case on two pages of the same website.
No regulator, exchange or ministry in India publishes a health-tech funding series. Every number quoted in a board paper, a press release or a market report begins life in a commercial tracker assembled from self-reported and press-reported rounds, each tracker using its own definition of the sector and each revising its own history without notice. The practical consequence is that the level of Indian health-tech investment is not a known quantity in any year since 2021, and any figure presented as though it were should be read as one vendor's estimate. The shape of the series can be relied upon. The level cannot. This chapter sets out the disagreements year by year, because a reader who has seen them will not again accept a single funding figure as a fact.
Take 2021, the peak year and the one most often cited. Tracxn put it at USD 3.2 billion in a March 2023 report, and at about USD 3.05 billion on its live page in November 2026. Inc42 put the same year at USD 2.19 billion. The spread on a single, closed, five-year-old year is roughly one billion dollars, which is a third of the larger figure. Nothing has changed in 2021 since 2021; what has changed is the definition of what counts and the completeness of the collection.
For 2022, Tracxn reported USD 1.4 billion and a fall of 55 per cent, while Venture Intelligence reported USD 1.07 billion. For 2023, three figures exist for one year, two of them from the same vendor: USD 438.2 million
in the Tracxn annual report, USD 537 million on the Tracxn live page, and USD 682 million from Venture Intelligence. The highest is 56 per cent above the lowest. For 2024, the Tracxn annual report gives USD 1.0 billion, the Tracxn live page gives USD 1.23 billion and Inc42 gives over USD 700 million, a divergence of about 75 per cent between the extremes.
For 2025 the live Tracxn page gives USD 863 million while Inc42 gives about USD 700 million across 54 deals, a gap of some 23 per cent. The reasons for these gaps are not mysterious, and they are not errors in the ordinary sense. A tracker has to decide whether a diagnostics chain, a pharmacy delivery business, a hospital group raising private equity, a medical device maker and an insurance distributor belong in health-tech, and the trackers decide differently. It has to decide whether to count debt, venture debt, secondary transactions and undisclosed rounds, and whether to carry an estimate where a round is unannounced. Each decision is defensible on its own; the aggregate is not comparable.
The clearest single illustration is the current year. For 2026 to date, one Tracxn page reports USD 626 million across 114 rounds to September 2026 and describes the trend as up 22.4 per cent. Another Tracxn page reports USD 742 million across 52 rounds to August 2026 and describes the trend as down 10.4 per cent. Same vendor, two pages, opposite directions, different round counts, overlapping periods. It is to be noted that both figures are in current circulation and that neither carries a reconciliation.
| Year | Figures in circulation | Spread |
|---|---|---|
| 2021 | USD 3.2bn (Tracxn, March 2023); about USD 3.05bn (Tracxn live, November 2026); USD 2.19bn (Inc42) | About USD 1bn |
| 2022 | USD 1.4bn, down 55 per cent (Tracxn); USD 1.07bn (Venture Intelligence) | About 31 per cent |
| 2023 | USD 438.2mn (Tracxn annual); USD 537mn (Tracxn live); USD 682mn (Venture Intelligence) | About 56 per cent |
| 2024 | USD 1.0bn (Tracxn annual); USD 1.23bn (Tracxn live); over USD 700mn (Inc42) | About 75 per cent |
| 2025 | USD 863mn (Tracxn live); about USD 700mn across 54 deals (Inc42) | About 23 per cent |
| 2026 to date | USD 626mn, 114 rounds to September, called +22.4 per cent; USD 742mn, 52 rounds to August, called -10.4 per cent | Opposite signs |
Every figure in the table above is tracker-derived. Tracxn, Venture Intelligence and Inc42 are commercial data vendors; none of the figures is filed with, audited by or published by any Indian authority, and the spreads shown are arithmetic comparisons of published claims rather than any vendor's own statement of error.
What cannot be concluded is anything that requires a level. The size of the market in any year cannot be stated. Year-on-year growth rates cannot be
calculated, because the numerator and denominator may come from different collections or from the same collection at different vintages. Health-tech's share of total Indian venture funding cannot be computed. Comparisons with other countries' health-tech funding, which rest on different trackers again, cannot be made. And no figure in the series is cash in a company: these are announced rounds, not drawn-down capital, and announcement is where the tracker's information ends.
What can be concluded is the shape, because every tracker agrees on it: a peak in 2021, a collapse in 2022, a trough in 2023, a partial recovery in 2024, and flat to down through 2025 and 2026. Three independent collections, however differently they define the sector, produce the same contour. That contour is enough to support a qualitative judgement, namely that Indian health-tech is five years past its funding peak and has not returned to it, and that the recovery of 2024 did not continue.
For a buyer the point is narrower and more useful than market sizing. Funding totals are routinely offered as evidence of a vendor's durability, both by the vendor and by its competitors, and they cannot carry that weight: the number is an estimate of announced capital at the sector level, it says nothing about the individual counterparty's cash position, and it may be revised after the contract is signed. The test that does carry weight is the filed one. Annual accounts, audited revenue, reported losses and the direction of both are published for every company of consequence in this sector, and the following chapter uses them. Where the choice is between a tracker's estimate of what went into a sector and a company's own filing of what came out, the filing wins.
The hospital groups set the baseline. Apollo Hospitals reported FY2026 revenue of Rs 25,229 crore, EBITDA of Rs 3,769 crore and profit after tax of Rs 1,942 crore, up 34 per cent. Fortis reported revenue of Rs 9,127.84 crore, EBITDA of Rs 2,085 crore at a 22.8 per cent margin and profit after tax of Rs 1,064.19 crore. Max Healthcare reported gross revenue of Rs 10,538 crore, EBITDA of Rs 2,638 crore at 26.2 per cent and profit
after tax of Rs 1,631 crore. Narayana Hrudayalaya reported revenue of Rs 7,896.0 crore, up 44 per cent on the acquisition of Practice Plus Group Hospitals in the United Kingdom, with reported profit after tax of Rs 810.5 crore and an adjusted figure of Rs 937.4 crore.
On filed FY2026 results the profitable parts of Indian healthcare are hospitals, diagnostics, pharmacy retail and insurance. Not one pure-play digital health platform has published a profit-after-tax-positive full year.
The profit in Indian healthcare sits with the asset owners and the risk carriers, and not with the platforms. For the year to 31 March 2026 every large listed hospital group, every listed diagnostics chain of scale, the largest listed pharmacy retailer and the listed health insurers reported a profit after tax. No pure-play Indian digital health platform has published a profit-after-tax-positive full year, and the nearest approach is an adjusted earnings measure sitting above a net loss of Rs 520 crore. The party with the weaker balance sheet is usually the one seeking a multi-year commitment and holding the patient data.
Apollo HealthCo is the only disclosed digital-arm segment among the listed hospital groups, and therefore the only place where the economics of an Indian digital health business can be read inside a profitable parent. It reported fourth-quarter FY2026 revenue of Rs 2,848 crore with EBITDA of Rs 156 crore against Rs 36 crore a year earlier, while segment profit after tax for FY2025 was negative Rs 27 crore. The cost of Apollo 24|7 was disclosed at Rs 425.5 crore for the twelve months to December 2024, and a demerger listing is targeted for the fourth quarter of FY2027. The strongest digital franchise in Indian healthcare, carried inside the strongest hospital group, has thus reached segment EBITDA positivity and is not yet demonstrably profitable in its own right.
Diagnostics and pharmacy retail are profitable on thinner absolute numbers. Dr Lal PathLabs reported FY2026 revenue of Rs 2,762.9 crore and profit after tax of Rs 509.8 crore, Thyrocare Rs 829.04 crore and Rs 162.85 crore, up 81 per cent, and Krsnaa Diagnostics Rs 772.8 crore and Rs 101.3 crore. MedPlus reported revenue of Rs 6,892.5 crore and profit after tax of Rs 219.6 crore across 5,330 stores, a roughly 3 per cent net margin on a physical network. Metropolis FY2026 could not be reliably sourced; its FY2025 revenue was Rs 1,346 crore with profit after tax of Rs 145 crore.
The risk carriers and distributors are profitable too. PB Fintech reported revenue of Rs 6,794 crore and profit after tax of Rs 670 crore, up 115 per cent, on premium of Rs 29,934 crore. Star Health reported gross written premium of Rs 20,369 crore, Ind AS profit after tax of Rs 911 crore and a combined ratio of 98.8 per cent; the normalised profit after tax of Rs 1,222 crore in its investor deck is company-defined. Niva Bupa reported IFRS profit after tax of Rs 366.10 crore on premium of Rs 9,432.9 crore. Medi Assist, the third-party administrator, reported revenue of Rs 904.8 crore with reported profit after tax of Rs 89.3 crore, down on the year, and an adjusted figure of Rs 68.8 crore. It is the only company here whose adjusted profit is lower than its reported profit, every other adjustment in the sector moving in the company's favour.
PharmEasy, filing as API Holdings, reported FY2026 revenue of Rs 6,618.5 crore and a net loss of Rs 520 crore in its annual report, an improvement of 67 per cent on the previous year's Rs 1,572 crore loss, with group EBITDA of positive Rs 62.5 crore. Tata 1mg reported FY2025 revenue of Rs 2,392 crore and a loss of Rs 276 crore, disclosed through the Tata Sons annual report. Figures for Practo, Pristyn Care and HealthifyMe are not publishable. Stated strictly: not one pure-play Indian digital health platform has published a profit-after-tax-positive full year, and the closest case is adjusted-EBITDA positive while losing Rs 520 crore after tax.
| Company | FY2026 revenue | FY2026 profit after tax |
|---|---|---|
| Apollo Hospitals | Rs 25,229 cr | Rs 1,942 cr |
| Max Healthcare | Rs 10,538 cr gross | Rs 1,631 cr |
| Fortis | Rs 9,127.84 cr | Rs 1,064.19 cr |
| Narayana Hrudayalaya | Rs 7,896.0 cr | Rs 810.5 cr reported |
| MedPlus | Rs 6,892.5 cr | Rs 219.6 cr |
| Dr Lal PathLabs | Rs 2,762.9 cr | Rs 509.8 cr |
| Thyrocare | Rs 829.04 cr | Rs 162.85 cr |
| PB Fintech | Rs 6,794 cr | Rs 670 cr |
| Star Health | Rs 20,369 cr premium | Rs 911 cr Ind AS |
| API Holdings, PharmEasy | Rs 6,618.5 cr | Loss of Rs 520 cr |
| Tata 1mg, FY2025 | Rs 2,392 cr | Loss of Rs 276 cr |
The FY2026 figures above are taken from results releases as relayed by trade press and should be reconciled against the companies' own exchange filings before being quoted in a transaction document. Reporting bases differ: Star Health is given on Ind AS, Niva Bupa on IFRS, and normalised or adjusted figures are company-defined in each case.
Valuation resets complete the picture. PharmEasy was valued at USD 5.6 billion at its 2021 peak; the April
2024 rights issue of Rs 1,804 crore, led by Ranjan Pai's MEMG, was struck at roughly a 90 per cent haircut implying about USD 500 to 600 million. A Goldman Sachs covenant default was reported in June 2023 and the IPO papers were recalled. Capital has meanwhile moved to assets: Narayana acquired Practice Plus Group Hospitals for GBP 183 million, announced 31 October 2025, and Apollo bought the International Finance Corporation's 30.58 per cent of Apollo Health and Lifestyle for Rs 1,250 crore in September 2025.
The takeaway is a diligence instruction, not an investment view. Where a platform is to hold clinical records, operate a consent flow or stand between a provider and a payer, its filed accounts belong in the evaluation alongside its functionality, as does the contractual answer to what happens to the data if it fails. The sector's exits argue for the question: JiviAI is listed as having closed in June 2026 after raising about USD 2.99 million, mfine is reported to have shut after USD 97 million, and DPIIT data cited in reporting puts healthcare and life-sciences closures at 553 as at 31 January 2026. None of the three is primary-sourced, and each is offered only as a reason to ask.
PM-JAY is a growing payer whose package rates have not been revised since 2022 and whose payment timeliness is now before two High Courts. For a provider the scheme is a credit decision before it is a volume decision.
The commercially significant facts about PM-JAY are not its scale but its price and its payment behaviour. Base package rates have not been revised since 2022, which is four years of flat tariffs against medical inflation. Payment delays have moved from complaint to litigation, with the Punjab and Haryana High Court issuing notices in 2026 over persistent and systemic delays and the Himachal Pradesh High Court ordering release within three weeks. And no official figure for unpaid dues exists in the public record, so a provider cannot size its exposure from published data. A hospital deciding whether to deepen its empanelled share is therefore making a receivables judgement on incomplete information, and should price it accordingly.
The budget sets the ceiling. The 2026-27 budget estimate for PM-JAY is Rs 9,500 crore, up 5.56 per cent on the revised estimate for 2025-26, according to the government release of 1 February 2026. The same release puts the Health Ministry total at Rs 1,06,530.42 crore, the National Health Mission at Rs 39,390 crore and PM-ABHIM at Rs 4,770 crore. The digital health mission appears at Rs 350 crore in budget estimate against Rs 324.26 crore revised: a Rs 350 crore line inside a Rs 1.07 lakh crore ministry. Anyone assuming the mission commands significant central money should read that line twice.
Allocation has also historically exceeded spending. Between 2019 and 2022 the revised estimate ran at roughly half the budget estimate in each year, on analysis by PRS and the Accountability Initiative. The exact series must be rebuilt from the Expenditure Budget volumes, but the pattern is consistent enough to matter: a rising budget estimate is a statement of intent, not a cash forecast.
Scale, by contrast, is real and documented. As at 28 February 2026 the scheme recorded 36,229 empanelled hospitals, 19,483 of them public and 16,746 private, and 11.69 crore admissions authorised, of which 6.74 crore were in private hospitals, on figures relaying a government release of 23 March 2026. Private hospitals therefore carry about 58 per cent of authorised admissions while holding 46 per cent of empanelment, the clearest published indication of how far the scheme depends on private capacity. Ayushman Vay Vandana, launched on 29 October 2024 to cover those aged 70 and over for Rs 5 lakh, had issued 1.14 crore cards by 28 February 2026 against a quoted target of about 6 crore seniors.
Health Benefit Package 2.2 took effect in November 2021. The 2022 revision raised 832 rates, cut 122, left 630 unchanged and introduced differential pricing by city tier. No revision after 2022 has been located, and none is scheduled in any published document. For a provider that means the reimbursement for a procedure performed in 2026 is set at a 2022 price, with consumables, salaries, device costs and energy all having moved in the interim. Where an empanelled hospital's PM-JAY share rises, its blended realisation falls, and the effect compounds in the tiers where differential pricing already set the lower rate.
The payment record is documented by the Comptroller and Auditor General. The performance audit tabled in August 2023 found inordinate delays in
settlement, 39.57 lakh claims processed beyond the 12-hour pre-authorisation window, excess payment of Rs 57.53 crore in four states, and 88,760 patients recorded as having died during treatment against whom 2,14,923 subsequent claims were nonetheless registered. The scheme's own rule is settlement within 15 days, extendable to 30. The audit establishes that the rule was not being met at the time of audit; nothing published since establishes that it is being met now.
The courts have since taken it up. The Punjab and Haryana High Court issued notices in 2026 over persistent and systemic delays. The Himachal Pradesh High Court ordered release of dues within three weeks and, significantly for any provider negotiating with a state health agency, barred both a pending vigilance inquiry and want of funds as grounds for withholding payment. The sharpest datapoint is commercial rather than judicial: about 650 private hospitals in Haryana suspended new admissions for 24 hours on 1 and 2 September 2026 over roughly Rs 1,200 crore pending beyond six months, as reported by Tribune India. A 24-hour withdrawal of admissions by 650 hospitals is a measure of leverage, used because ordinary remedies had not worked.
The CAG findings are drawn from the performance audit tabled in August 2023; the report number could not be confirmed and is therefore not cited. The Haryana pending figure of roughly Rs 1,200 crore is a single press source for one state and is not a national total. No official figure for unpaid PM-JAY dues, at any level, has been published. The Ayushman Vay Vandana card count and the senior-population target are from reporting; no official document was obtained.
| PM-JAY as a counterparty | Published position |
|---|---|
| Budget estimate 2026-27 | Rs 9,500 crore, up 5.56 per cent on revised estimate |
| Empanelled hospitals, 28 February 2026 | 36,229: 19,483 public, 16,746 private |
| Admissions authorised, 28 February 2026 | 11.69 crore, of which 6.74 crore private |
| Last package rate revision | 2022 |
| Settlement rule | 15 days, extendable to 30 |
| Claims beyond the pre-authorisation window, CAG | 39.57 lakh |
| Official unpaid dues figure | None published |
The takeaway is that PM-JAY should be underwritten and not merely joined. The questions that follow from the published record are the age profile of the
provider's own outstanding claims, the state agency's settlement history as against the 15-day rule, whether the current case mix remains viable at 2022 rates and what proportion of capacity can be exposed to a single payer whose budget estimate has historically been halved at revision. None of those questions can be answered from a national dataset, because the national dataset does not exist. They can be answered from a provider's own ledger, and that is where the work has to be done.
The private payer, for comparison, works to published turnaround times: under the IRDAI master circular of 29 May 2024, cashless pre-authorisation within one hour, discharge authorisation within three hours and non-cashless settlement within 15 days. No penalty is published for breaching the one-hour or three-hour standard, and the Rs 1 crore per breach figure quoted by vendors is the general section 102 power.
Enterprise hospital software pricing in India is not published anywhere. The clearest public money in the field runs in the opposite direction: incentives paid to facilities for linking records.
A buyer cannot benchmark the price of an Indian hospital information system from public sources, because no Indian enterprise vendor publishes a rate card. Insta by Practo, KareXpert, Medixcel, DocEngage, Attune, Napier, Suvarna, Birlamedisoft and Plus91 are all quote-only. Bahmni, the open-source alternative, has a licence cost of zero and no published Indian implementation cost. What does exist in public is the money moving the other way: the Digital Health Incentive Scheme, which pays facilities and software companies for linking records and whose disbursement is published. Price discovery on the buying side has to be done by tender, and this chapter sets out what can honestly anchor one.
The figures that circulate as Indian software pricing are marketing ranges from comparison blogs, several of them written by competing vendors, and they should be labelled as such. One such page gives Rs 1,499 to Rs 15,000 per facility per month, or Rs 200 to Rs 500 per user per month (adrine.in, 2026). Another gives Rs 2,000 to Rs 8,000 a month for clinics and Rs 8,000 to Rs 25,000 for hospitals (cufront.com, 2026). These are small-business cloud ranges, not transaction prices. No enterprise contract value for an Indian hospital information system has been found in the public domain.
One integration-cost estimate exists, and deserves quoting precisely because it is the only one. Kommuru and Agarwal, in Health Management Policy and Innovation 11(2) of 9 July 2026, from the Stanford Graduate School of Business, state that integration costs for mid-sized providers are estimated at Rs 30 to 50 lakh, derived from 15 interviews conducted between January and March 2026. It is interview-derived rather than a tender price, and covers integration and not the underlying system.
The Digital Health Incentive Scheme is where government money in Indian digital health can actually be read. A government backgrounder of 6 July 2026 reports disbursement as at 18 June 2026 of Rs 107 crore and above to hospitals, Rs 2.95 crore to diagnostics, labs and pharmacies, and Rs 26 crore and above to digital solution companies. The distribution is itself a finding: hospitals have claimed the overwhelming share, diagnostics and pharmacy have barely engaged, and software vendors collected roughly a quarter of the hospital total, consistent with a design that pays the vendor a share of the facility's incentive.
The rate structure is widely reported and was not read from the authority's own document. On the original 2022 terms, a facility earned Rs 20 per ABHA-linked record above a floor of 100 linking transactions a month; a digital solution company took 25 per cent of the facility's incentive; an NHCX claim transaction earned Rs 500 or 10 per cent of claim value, whichever was lower; and a cap of up to Rs 4 crore applied per entity. Corrigendum 6, dated 20 November 2025 under reference S-12021/070/2022-ABDM(Coord)-Part(2), exists, but the document would not render, so only its existence and date can be cited.
What happened to the rates afterwards is not properly public, and the direction matters to anyone who has written incentive income into a business case. A Corrigendum 7, said to cover April to September 2026 and to cut payment to Rs 10 per KYC-verified linked discharge summary, Rs 5 for other record types and Rs 200 per PM-JAY claim, is described only by third-party guides, though a Rajasthan Directorate letter of 5 May 2026 corroborates the shift to paying only for KYC-linked records and adds per-day and per-month caps. The expiry date is not clearly public either: the last confirmed extension runs to 31 December 2023, yet payments were flowing in June 2026.
Milestone one, two and three certification through the authority's sandbox is free; the vendor's own cost of achieving it is not public. The Corrigendum 7
rates above are third-party descriptions of a document that could not be obtained and should not be relied upon in a budget.
| Published price or payment | Figure | Status |
|---|---|---|
| Digital Health Incentive Scheme, hospitals | Rs 107 crore and above disbursed | Government backgrounder, as at 18 June 2026 |
| Same scheme, diagnostics, labs, pharmacies | Rs 2.95 crore disbursed | Government backgrounder, as at 18 June 2026 |
| Same scheme, digital solution companies | Rs 26 crore and above disbursed | Government backgrounder, as at 18 June 2026 |
| Original incentive rate | Rs 20 per ABHA-linked record, cap up to Rs 4 crore | Widely reported, not read from the authority's document |
| Integration cost, mid-sized provider | Rs 30 to 50 lakh | Interview-derived estimate, July 2026 |
| Hospital information system, small business | Rs 1,499 to 15,000 per facility per month | Marketing range on a comparison blog |
| Enterprise hospital system contract value | Not published | No Indian vendor publishes a rate card |
| Assam medical college hospital system | About Rs 56.71 crore, seven hospitals | Award to RailTel, reported 2 January 2026 |
Public tendering gives two anchors and no more. The only confirmed 2026 award is to RailTel Corporation, at about Rs 56.71 crore, for a hospital management information system covering seven medical college hospitals, awarded by Assam's Medical Education and Research Department and reported on 2 January 2026. Kerala's eHealth programme carried an original cost of about Rs 96 crore, 90 per cent centrally funded, with a later Rs 100 crore sanction to extend it to 349 more hospitals; the Rs 3,000 crore World Bank-assisted programme in the state government order of 1 July 2023 is a different thing. Nothing verifiable was found elsewhere.
Service prices are thinner still. Published consultation list prices exist, from Rs 199 upwards on the large private platforms and free to the citizen on the government channel, but contract and per-consultation rates between businesses are not public. On diagnostics the operative government schedule is the CGHS revision notified on 13 October 2025, with outpatient consultation at Rs 350 and super-specialist consultation at Rs 700, clarified by an order of 13 January 2026 that confines the Rs 700 to a recognised DM or MCh consultation and caps inpatient consultations at two a day per specialist. Where operators disclose realisation it is more useful than any list price: Dr Lal PathLabs reported revenue per patient of Rs 976 in the quarter to September 2026, up from Rs 889, at 3.09 tests per patient.
Three costs cannot be priced at all from public sources, and each is routinely asserted: insurer and administrator cost per claim, the NHCX transaction cost, and PM-JAY administrative cost per claim. The only per-claim figure in circulation is the incentive payable under the Digital Health Incentive Scheme, a payment to a hospital and not a processing cost, and several vendor blogs conflate the two. What can be cited is the problem rather than the price: the approximately 45-day average claim settlement cycle recorded in the July 2026 journal paper is what the claims exchange is meant to compress. A buyer should treat every cost-per-claim saving quoted to it as unevidenced until the vendor produces the baseline.
eSanjeevani has recorded 50 crore consultations, which makes it the largest public teleconsultation service anywhere. What is published is a cumulative total and a current daily range, and from those two numbers no trend can be derived.
The public teleconsultation figure is genuine, large and almost useless for forecasting. A government release of 6 October 2026 records that eSanjeevani crossed 50 crore consultations on 15 September 2026, at 50,00,92,730 cumulative teleconsultations across all 36 states and union territories. That establishes capacity beyond argument. What it does not establish is direction, because the government publishes a cumulative total and a current daily range and nothing in between: no monthly series, no annual series, no state-by-state time series. A reader can therefore say with confidence that the service is very large, and cannot say whether it is growing, flat or declining. Anyone who asserts the third option is inferring, and this chapter sets out why the inference should not be made in public.
The published network is substantial. The same release records more than 1.42 lakh Ayushman Arogya Mandir spokes, 19,473 medical hubs, 901 online outpatient departments, 2,41,923 registered providers and service in 15 languages, with artificial intelligence clinical decision support integrated. The system was built by C-DAC Mohali. The operating rate is given as
approximately 2.5 to 3 lakh consultations a day, with a peak single day of 6,30,315. On utilisation, women account for 57.14 per cent of consultations and 16.25 per cent of users are aged 60 and over, which is a demographic profile no private platform has published and which is itself the strongest evidence that the service reaches populations commercial telemedicine does not.
The arithmetic problem is simple and worth stating plainly, because it recurs in every market report that quotes this figure. A cumulative total is the integral of a flow that has been running since 2019. A current daily range is an instantaneous reading. Dividing the first by elapsed time yields an average that necessarily understates recent years if the service grew and overstates them if it declined, and comparing that average with the current daily range tells a reader only that the two are not identical. Without at least one intermediate dated total, no growth rate can be computed. A plateau is consistent with the published numbers; so is continued growth; and neither has been published.
The outpatient versus hub-and-spoke split is not in the 6 October 2026 release and could not be sourced elsewhere. The distinction is commercially significant, since a facility-mediated consultation at a health and wellness centre and a direct citizen consultation through an online outpatient department have different cost structures, different clinical scope and different implications for a hospital group's referral flow. The mix is therefore unknown.
Unit economics are also unavailable. eSanjeevani is free to the citizen, and its cost per consultation is not public. More than Rs 100 crore was allocated to the service in FY2020-21, according to a parliamentary reply reported in September 2020, but dividing an early-year allocation by a cumulative total accumulated over six subsequent years would fabricate a unit cost rather than compute one. That calculation appears in circulation and should be refused. What can be said is that the state has demonstrated willingness to fund teleconsultation at no charge to the patient, which sets the reference price any commercial service competes against in the public-facing segment.
Private teleconsultation volumes in India are effectively not public. Neither Apollo 24|7 nor Practo has published platform-level consultation counts in recent years. What is published is list pricing: Apollo 24|7 starts at Rs 200, Practo starts at Rs 199 with concern-specific listings running up to Rs 849, and Tata 1mg is quoted at Rs 199 to Rs 799 on third-party comparison pages only. Contract rates for corporate or insurer-funded teleconsultation are not published by anyone. The consequence is that the private market cannot be sized from the volume side or the value side, and that
any market-size figure for Indian teleconsultation is constructed rather than observed.
The regulatory frame has not kept pace with the volume, which is its own finding. Fifty crore consultations have been delivered under practice guidelines dated 25 March 2020, issued as an appendix to conduct regulations of 2002. The successor instrument, the National Medical Commission's conduct regulations notified on 2 August 2023, was held in abeyance three weeks later and no replacement has been issued. India therefore runs the largest public teleconsultation programme in the world on an instrument drafted in the first month of the pandemic.
| eSanjeevani, published | Figure |
|---|---|
| Cumulative teleconsultations at 15 September 2026 | 50,00,92,730 |
| Coverage | All 36 states and union territories |
| Spokes, hubs, online outpatient departments | 1.42 lakh and more, 19,473, 901 |
| Registered providers | 2,41,923 |
| Current daily range | About 2.5 to 3 lakh |
| Peak single day | 6,30,315 |
| Women as a share of utilisation | 57.14 per cent |
| Users aged 60 and over | 16.25 per cent |
| Monthly or annual series | Not published |
| Cost per consultation | Not public |
One adjacent claim is worth examining because it is the one most often used to justify digital investment at the front desk. A study by IIHMR, cited in the government backgrounder of 6 July 2026, reports that Scan and Share reduced waiting times from about one hour to between two and five minutes, against 23.21 crore tokens generated as at 18 June 2026. The study itself could not be located. Set against it, the July 2026 journal paper records a counter-finding: congestion is redistributed to specialist referral desks rather than eliminated. Both can be true. A registration queue can be dissolved while the bottleneck moves downstream, and a buyer evaluating a queue-management investment should ask which of the two outcomes the vendor is measuring.
The takeaway is a reporting demand rather than a conclusion. The government has built and operates the largest public teleconsultation service in the world, and it publishes the two numbers least useful for planning around it. What a hospital group, a state department or an insurer needs before committing capacity is the monthly series, the outpatient versus spoke split, the repeat-consultation rate and the referral conversion rate into physical care. None of those is published. Until they are, the honest position is that teleconsultation in India has demonstrated scale and has not demonstrated a trend, and any projection built on the 50 crore figure is a projection built on one point.
The Gulf states attached health data connection to licensing and claim submission. India did not. India nonetheless linked more than a billion records at a health spend per head under one twentieth of the Gulf's.
The single difference between Gulf health data exchange and Indian health data exchange is not technology, funding or ambition: it is that connection in the Gulf is a condition of being allowed to operate and be paid, and in India it is voluntary. In Abu Dhabi a facility that does not connect to Malaffi cannot renew its Department of Health licence, and a facility with a Daman agreement cannot submit claims until the connection is complete. In Dubai, connection to Nabidh is a Dubai Health Authority licence condition. The Indian mission's equivalent published figure is more than 450 voluntary integrations with no licensing consequence of any kind. The outcomes follow the incentives, and so does the cost, which runs in India's favour.
Malaffi is a Department of Health initiative operated by Abu Dhabi Health Data Services, a partnership between the Department and Injazat now within M42. It went live at the end of July 2019, six months after the Orion Health contract, and by 14 August 2025 held 3.5 billion clinical records and 12.7 million unique patient profiles. The Department announced in September 2024 that all Abu Dhabi facilities were connected; LOINC adoption was reported at 90 per cent on 27 October 2026. Connection requires an Accession Agreement, a Malaffi security assessment, an HL7-capable electronic medical record and an Etisalat SD-WAN link.
Nabidh in Dubai had exceeded 10.41 million records by the end of June 2025, across 1,888 licensed facilities, 53,659 professionals and 91 connected electronic
medical record systems. Under the Authority's standard DHA/HISHD/ST-09, facility upload does not require patient consent and patients may opt out, the mirror image of the Indian consent architecture. The penalty range of AED 500 to AED 500,000 quoted in commentary traces only to vendor and law-firm blogs; the published levers are warning letters, compliance orders and licence non-renewal.
Riayati, operated by the Ministry of Health and Prevention, shows that the Gulf is not immune to the reporting problems described elsewhere in this edition. Its dashboard, last updated October 2024, gives 4.00 billion connected records, 14 million unique patients, 116,071 clinicians and 4,952 facilities, while the narrative on the same page refers to more than 3,000 facilities. What is substantive is that Riayati is integrated with Nabidh, Malaffi and the federal identity authority, the nearest published identity link in this comparison and the thing India's voluntary, consent-based ABHA does not have.
Saudi Arabia's NPHIES is the most instructive case for an insurer or a hospital finance function, because it is a claims platform rather than a record exchange, and its implementation guide, generated on 3 December 2025, is published. As at October 2025 the Council of Health Insurance regulated 6,600 provider organisations, 28 insurers and 8 third-party administrators, serving about 14.1 million beneficiaries. Onboarding stood at more than 6,419 provider facilities, 25 insurers and more than 60 software vendors, with claims market share of 98 per cent and authorisation adjudicated within 30 minutes in 96 per cent of cases. Transaction volumes were 143 million in 2023 and 292 million in 2024, with 96 million in the first quarter of 2025 alone.
Two points about NPHIES are usually misreported. It runs FHIR R4 through a centralised validating gateway with no peer-to-peer exchange, and it does not determine fraud: it flags suspicious transactions for payers and does not adjudicate. Fraud-reduction figures, platform cost and funding model are not public, and no onboarding deadline for 2026 to 2028 has been published.
The Saudi citizen channel figures require care. Sehhaty passed 31 million users in 2025, but peer-reviewed Ministry of Health data show ministry telemedicine consultations rising from about 3.1 million in 2019 to 8.8 million in 2021 and then falling to 4.3 million in 2023, with the 937 service carrying 86.1 per cent and Sehhaty 11.53 per cent. The circulating figure of 51 million virtual consultations is not sourced to the ministry. The Guinness World Records recognition of Seha Virtual Hospital, announced 21 October 2024, is an award announcement and not an audited capacity measure.
The spend comparison should reframe the discussion. On WHO Global Health Expenditure Database figures for 2023, current health expenditure per capita in
current US dollars was USD 2,401.52 in the UAE, USD 1,825.25 in Saudi Arabia, USD 1,804.35 in Qatar and USD 84.69 in India: the UAE spends roughly 28 times what India spends per head. Against that, India had linked more than 100 crore records to ABHA as at 22 May 2026, doubled from 50 crore in February 2025, against 97.6 to 97.8 crore identifiers issued. No Gulf system has attempted linkage at that scale.
| Dimension | Gulf position | Indian position |
|---|---|---|
| Connection | Licence renewal and claim submission blocked without it | Voluntary, more than 450 integrations, no consequence |
| Identity | Riayati integrated with the federal identity authority | ABHA voluntary and consent-based |
| Records per head | Abu Dhabi: 3.5 billion records, 12.7 million patients | Over 100 crore records against 97.6 to 97.8 crore ABHA |
| Payer | Saudi gateway carries 98 per cent of claims; UAE cover mandatory in all seven emirates from 1 January 2025 | Mixed: PM-JAY, private insurance, large out-of-pocket spending |
| Spend per head, WHO 2023 | UAE USD 2,401.52; Saudi Arabia USD 1,825.25; Qatar USD 1,804.35 | India USD 84.69 |
The Gulf is also ahead on data law, which is the direction the Indian obligations of 13 May 2027 follow. Oman's law became fully enforceable on 5 February 2026, with penalties up to OMR 500,000. Saudi Arabia's has been in force since 14 September 2023 with enforcement from 14 September 2024, treats health data as sensitive and requires breach notification within 72 hours. UAE executive regulations were unissued as at October 2026, but health data is excluded from the federal data law in any case: the operative regime is Federal Law No. 2 of 2019, whose Article 13 bars storing, processing or transferring UAE health data offshore without health-authority approval, in force from 16 May 2021.
Each system shows the other something, and both statements are factual rather than rhetorical. The Gulf demonstrates that near-universal connection is achievable within a few years when it is attached to licensing and claim submission, a lever India has not used nationally and could. India demonstrates that a billion record links can be assembled at a fraction of the per-head expenditure, at a scale no Gulf state has attempted. For a buyer operating across both, a Gulf facility's connectivity can be assumed from its licence while an Indian facility's must be verified. No published cost exists for Malaffi, Nabidh, Riayati or NPHIES, so no claim about what mandated connection would cost India can be supported.
Three figures circulate widely in Indian digital health and not one can be traced to a primary source. Each has a defensible replacement, and in each case the replacement is weaker, which is the point.
The three most-quoted statistics in Indian digital health cannot be sourced. One is a PM-JAY admissions and value figure that appears only on aggregator sites and contradicts the official count; one is a pending-dues figure that is almost certainly a measure of claims processed rather than claims unpaid; and one is an electronic medical record penetration figure attributed to a government body that appears never to have published it. All three are directionally plausible, which is why they survive, and all three are repeated most often by parties with an interest in the direction they point. What follows traces each to its origin and states the defensible alternative, which in every case is a smaller claim or an admission that no figure exists.
The claim, usually dated September 2026 and extended to more than 38,000 hospitals, appears only on aggregator sites. It cannot be traced to any government release or to the National Health Authority, and it is inconsistent with the official count published seven months earlier. The authority's own position as at 28 February 2026, relayed through a government release of 23 March 2026, was 11.69 crore admissions authorised across 36,229 empanelled hospitals. An increase of 1.56 crore admissions in seven months is not impossible, but it is unverified, and the rupee value has no counterpart in any official statement.
The defensible statement is the official one, with its date attached: 11.69 crore admissions authorised, of
which 6.74 crore in private hospitals, across 36,229 empanelled hospitals, 19,483 public and 16,746 private, as at 28 February 2026. No cumulative rupee value of authorised claims should be asserted, because none has been published on a traceable basis.
This figure, usually given across 63,89,517 claims and attributed to a reply to a right-to-information request made to the National Health Authority, is the most consequential of the three, because it is quoted in support of the proposition that the scheme is close to insolvent on its obligations. The underlying reply has not been obtained. The figure is close to the whole scheme's cumulative authorised value, which makes it almost certainly a measure of total claims processed rather than of unpaid dues. A cumulative processed value and an outstanding payable differ by orders of magnitude, and that conflation is the error.
The defensible statement is that no official figure for unpaid PM-JAY dues exists at any level. What can be cited, with sources and dates, is narrower and more credible: roughly Rs 1,200 crore pending beyond six months in Haryana, reported by Tribune India around the suspension of new admissions by about 650 private hospitals on 1 and 2 September 2026; notices issued by the Punjab and Haryana High Court in 2026 over persistent and systemic delays; an order of the Himachal Pradesh High Court requiring release within three weeks; and the Comptroller and Auditor General's performance audit tabled in August 2023, which found 39.57 lakh claims processed beyond the 12-hour pre-authorisation window. Those four make the argument the unsourced figure was being used to make, and they can be defended.
This statistic, usually rendered as fewer than 15 per cent of Indian hospitals having fully digitised medical records and attributed to NITI Aayog in 2024, appears in a vendor blog. No corresponding NITI Aayog document exists that could be found, and the figure could not be located in any NITI publication. Two related artefacts show how badly this corner of the literature is contaminated. A paper on a preprint repository claims that 76 per cent of Indian hospitals had adopted electronic health record systems in 2014, citing NITI Aayog; that is implausible on its face and is almost certainly a mis-transcribed United States figure. A widely
circulated split of 9 per cent rural against 60 per cent urban has no identifiable origin whatever.
The defensible statement requires a proxy and an admission. There is no authoritative, primary, current figure for the share of Indian hospitals running an electronic medical record, and saying so is the honest answer. The only usable proxy is the pair published by the digital mission in July 2026: 2.72 lakh of 5.33 lakh registered facilities were using mission-enabled software, set against roughly 1.4 million and more health establishments nationally. Both halves of that proxy need their caveats stated, namely that registry entries are self-declared and unverified, and that using enabled software is not the same as maintaining a record.
| The number in circulation | What it traces to | The defensible statement |
|---|---|---|
| 13.25 crore admissions worth Rs 2.03 lakh crore, 38,000+ hospitals | Aggregator sites only; inconsistent with the official February 2026 count | 11.69 crore admissions authorised across 36,229 empanelled hospitals, 28 February 2026 |
| Rs 1.21 lakh crore pending across 63,89,517 claims | An unobtained right-to-information reply; close to cumulative authorised value, so probably claims processed | No official unpaid-dues figure exists; cite the Haryana Rs 1,200 crore, the two High Court matters and the 2023 CAG audit |
| Fewer than 15 per cent of Indian hospitals have an EMR | A vendor blog attributing it to NITI Aayog; no such document found | No primary figure exists; the only proxy is 2.72 lakh of 5.33 lakh registered facilities on enabled software, July 2026 |
A fourth error of the same family travels in commentary rather than in numbers. There is a Comptroller and Auditor General performance audit of AB-PMJAY; there is no such audit of the digital mission, and several commentaries conflate the two. The Parliamentary Standing Committee's 144th Report of March 2023 criticised PM-ABHIM, the health infrastructure mission, for spending about 20 per cent of its budget estimates; it did not criticise the digital mission.
Four tests dispose of most of what circulates in this field, and they can be applied in the time it takes to read a slide.
The wider register of what is not available should be read alongside those tests. There is no primary Indian health-tech funding series. The CAG report number could not be confirmed. No health benefit package revision after 2022 was located, and no milestone three figure has been published. No insurer, administrator, authority or claims-exchange cost per claim exists in public. The eSanjeevani outpatient split, the incentive scheme's rate table and expiry date, tender values for every state except Assam and Kerala, Metropolis FY2026, private teleconsultation volumes, the published cost of any Gulf platform, and whether any Significant Data Fiduciary has been designated are all unavailable. No order imposing a penalty under the data protection law has been found, and none penalising an insurer for a missed health turnaround time. The credibility of a buyer's position rests on saying so.
A Call is a prediction written to be graded: falsifiable, dated, and confidence-rated. Ten for the year. The 2028 edition will mark each one hit, miss or partial.
A forward-look that refuses to mark its own homework is just a brochure. Volge Quarterly makes a small number of Calls and grades them in the open the following year.
Falsifiable. A Call states something that can be shown true or false by a named date: no unscoreable trend-talk. Dated. Every Call carries the year it resolves; here, the end of 2027. Confidence-rated. High, Medium or Low, so a contrarian low-confidence Call and a high-confidence base case are scored fairly. Sourced. The reasoning cites the sector evidence the Call rests on. Few, not many. Ten sharp Calls build a record; a page of forty hedged predictions grades to noise.
| Band | What it means | How to weight it |
|---|---|---|
| High | The base case; the evidence points one way | Treat as the planning assumption |
| Medium | Likely, but with a real path to being wrong | Hold, but hedge |
| Medium–High | Stronger than even, short of a base case | Lean in, watch the swing factor |
| Low | A contrarian or early Call, placed deliberately | Watch; do not yet build on it |
The 2028 edition opens with the Scorecard: each Call marked hit, miss or partial, with a running hit-rate by band.
Ten dated, falsifiable predictions for the year. Confidence is stated so a contrarian low-confidence Call and a high-confidence base case are read, and scored, differently.
Each Call draws on the sector data in Part I and on Volge's Rules of the Game regulatory tracker. Source material: Volge's internal sector playbook . No Scorecard in Vol. I: the 2028 edition grades these.
At least one Indian digital-health platform reaches sustained operating profitability at scale: a multi-segment player posting positive EBITDA for two consecutive quarters.
Confidence: Medium · Resolves end-2027
Capital has turned selective and rewards positive unit economics; only platforms owning pharmacy, diagnostics and teleconsultation together have the lifetime value to cross over, and the leaders are close.
Public-rail and business-to-business or business-to-government channels drive the majority of net new digital-health revenue growth, ahead of direct-to-consumer subscription.
Confidence: Medium–High · Resolves end-2027
With acquisition cost structurally above per-consult value, survival runs through corporate, government and infrastructure channels; 2027 is when that shift shows in the revenue mix.
Annual digital-health venture funding exceeds its ~$0.70 billion 2025 level and recovers past $1 billion, while deal count stays below the 2021 peak: capital concentrating in fewer, larger, economics-proven rounds.
Confidence: Medium · Resolves end-2027
The 2024 rebound to ~$1.13B across 112 deals did not hold: 2025 fell to about $0.70B across 54 deals (Inc42, 2026), and Tracxn records about $626M across 114 rounds to September 2026. The trajectory is up in value, down in count, as growth-at-any-cost loses funding.
AI scribes and diagnostic copilots are embedded in the majority of India's large teleconsultation and hospital platforms, shifting cost-to-serve by cutting per-consultation effort.
Confidence: High · Resolves end-2027
The technology is mature and the unit-economics pressure is exactly where it bites; clinician AI use already rose from ~12% to 41% in a year. The cheapest verifiable Call in the set.
The Digital Personal Data Protection regime becomes a gating diligence item for health data: at least one notable digital-health round or acquisition turns on DPDP and health-data readiness.
Confidence: Medium · Resolves end-2027
The DPDP Rules were notified on 13 November 2025 (G.S.R. 846(E)); consent-manager registration opens on 13 November 2026 and the substantive obligations commence on 13 May 2027, so the gate closes during the Call's window. Health data is the most sensitive category, so it is where compliance first becomes a price of entry rather than a checkbox.
The first credible pure-play digital-health public listing (API Holdings / PharmEasy the bellwether) either lists on demonstrated cash-flow positivity or slips again, but no profitless platform clears the public market.
Confidence: Medium · Resolves end-2027
API Holdings filed for up to ₹6,250 crore, withdrew in the correction, and a revival is conditional on turning cash-flow positive; the public market gates on the same profitability test as the private rounds.
The rules have sat un-notified since 2018 despite a 2023 Delhi High Court direction; institutional inertia and contested interests make status quo the base case, and valuations keep their regulatory discount.
Confidence: Medium–High · Resolves end-2027
The e-pharmacy draft rules remain un-notified through 2027, and the segment continues to operate under offline drug law: the single largest standing policy risk, unresolved.
Health insurtech remains the fastest-growing of the seven segments, and health insurance holds its place as the largest non-life line (>40% of premium) as OPD and group cover deepen.
Confidence: Medium–High · Resolves end-2027
Health overtook motor in FY25 at ~41% of non-life premium; group and out-patient cover are the structural growth vectors, and they are exactly the payer wedge digital health needs.
Between a fifth and a third of the ~11,000-firm base fails or is absorbed over the cycle, and the conglomerates (Tata, Reliance, the Manipal group) remain the defining acquirers.
Confidence: Medium · Resolves end-2027
~90% of the base is sub-scale; a disciplined capital market starves single-segment players, and strategic buyers provide the only reliable exit. The direction is not in question, only the pace.
The Unified Health Interface, launched on 29 June 2026, reaches material transaction volume, with open discovery-and-booking beginning to unbundle the closed platforms: a structural shift, not yet a dominant one.
Confidence: Low · Resolves end-2027
The network launched on 29 June 2026 with four citizen services live (PIB), so the architecture is no longer prospective and the Call now turns on volume rather than existence. Its effects remain nascent and depend on government pace, and it is placed to be graded honestly either way.
The Calls · Volge Quarterly 2027
The year read from four angles (the market, the technology, the rules and the capital) and then bracketed by a bull, a base and a bear case.
Four short outlooks, each drawn from one of Volge's running series, triangulate the year.
The sector enters 2027 at roughly $15–18 billion, scaling towards a $100 billion-plus figure by 2033 on severe care undersupply: 1.1 doctors per 1,000 against 2.8 in developed markets. The binding constraint is unit economics, not regulation or capital, and 2027 is the reckoning: value concentrates in the multi-segment platforms and the recurring-revenue segments, while the long tail of sub-scale firms thins.
Generative AI is the horizontal of the year. Voice of Volge's Applied AI thesis (that governance, not the model, gates value) lands cleanly in Indian digital health: the models are ready and frugal, and the work is consent, accuracy and liability. The AI scribe moves from novelty to default, and the cost to serve falls enough to make thin margins survivable.
The DPDP Rules, notified 13 November 2025 with substantive duties from 13 May 2027, move compliance from overhead to gate as they apply to health data, and the e-pharmacy vacuum persists as the largest standing policy risk. The Rules of the Game tracker carries both as active regimes; together they decide which models are financeable and which carry a regulatory discount.
Funding rebounded to ~$1.13 billion across 112 deals in 2024 and now rewards proven economics over growth, with the conglomerates as the defining
acquirers. The delivery proof (what actually ships and works in production) will be carried in Field Notes as Volge's engagements are written up behind the sign-off gate.
The Calls are the base case. Bracketing them with an optimistic and a pessimistic scenario shows what would have to be true for the year to break either way.
Two or more platforms cross into sustained profitability; AB PM-JAY teleconsultation reimbursement widens materially; the e-pharmacy rules are finally notified, removing the discount; and a credible IPO prints. Funding steps up and rotates decisively into provider software, chronic-care and insurtech. The sector exits 2027 with a proven profit template and a re-rating of the recurring-revenue segments.
The Calls hold. One platform reaches scale profitability, the cheap channels carry the growth, funding rises but concentrates, the AI scribe becomes standard, and the e-pharmacy vacuum persists. Consolidation thins the tail. The year is one of quiet repricing towards quality rather than a breakout.
Capital tightens further, the profitability crossings slip, and a funding air-pocket strands mid-stage firms with high acquisition costs and no payer. The e-pharmacy ambiguity hardens into enforcement risk, and a DPDP penalty or data incident chills enterprise demand. Attrition runs to the top of the 20–30% range, and the IPO window stays shut. The opportunity is intact; the timeline slips a cycle.
The swing factors are the same three: the pace of payer deepening (PM-JAY and group cover), the e-pharmacy notification, and whether one platform can print two clean profitable quarters. Move any of the three and the year moves with it.
By domain · Volge Quarterly 2027
From the year's read to the year's action: what to do, what the rules demand, and the numbers and terms behind the narrative.
Five moves follow directly from the Calls. They are written for the operator and the board, not the analyst.
Stop optimising acquisition cost in isolation and re-engineer lifetime value. Cross-sell into pharmacy and diagnostics, build the chronic-care relationship that recurs, and treat every acquired customer as a multi-segment annuity. The platforms that win in 2027 change the denominator of the LTV-to-CAC ratio.
Prioritise corporate group health, government volume and ABDM-native distribution over paid direct-to-consumer. A user who arrives through an employer at ₹300 and recurs annually repays in months; a user bought for ₹1,200 may never repay. Build for the channel, not the app store.
Treat DPDP and ABDM consent as features that win enterprise and government deals, not as a tax. The firms that can prove lawful, permissioned data will clear diligence the careless cannot, and that becomes a moat as the largest contracts move to the compliant.
The wedge into the unit-economics problem is the payer. Build the employer and insurer relationships, the OPD and group-cover rails, and the claims technology: the assets that put someone other than the patient on the other side of the transaction.
Adopt the AI scribe and triage layer now: it is becoming table stakes, it cuts cost to serve, and it stretches the scarce clinician. Position it as governed decision support, keep a clinician in the loop, and hold the line on accuracy and liability.
The seven segments mapped to their governing instruments and the current state of each: the single reference for regulatory exposure by segment.
| Segment | Primary regulation | Status / risk |
|---|---|---|
| 1 · Teleconsultation | Telemedicine Practice Guidelines 2020; state councils | Clear but state-fragmented; cross-state licensure friction |
| 2 · E-pharmacy | Draft e-pharmacy rules; Drugs & Cosmetics Act 1940 | Unsettled: rules never notified; highest policy risk |
| 3 · E-diagnostics | NABL / ISO 15189; Clinical Establishments Act | Accreditation-led; clear |
| 4 · Provider software | ABDM standards; DPDP Act 2023 | Interoperability and data governance |
| 5 · Chronic-care & RPM | DPDP Act; device rules where hardware is involved | Mixed; clear for software |
| 6 · Wellness & preventive | Consumer-protection; advertising standards | Light-touch |
| 7 · Insurtech & claims | IRDAI regulations | Regulated; established |
Sources: MoHFW; CDSCO; DPDP Act 2023; IRDAI. Current to June 2026.
E-pharmacy notification: pending since 2018, court-directed since 2023; the single largest swing factor. DPDP Rules: operationalisation for health data; consent, localisation, deletion; penalties to ₹250 crore. PM-JAY teleconsultation reimbursement: expansion beyond select states would re-rate the segment. IRDAI OPD and senior-cover measures: the payer-deepening signal to track.
The quantitative picture in one place, on the reconciled basis used throughout. Ranges denote genuine source disagreement on scope.
| Metric | Value | Basis |
|---|---|---|
| Market size (2025) | ~$15–18B | Broad digital-health scope |
| 2033 projection | $100B+ | ~25% CAGR |
| Telehealth sub-market (2025) | ~$3.9B → ~$9.8B (2030) | ~20% CAGR (Mordor) |
| Startups | ~11,000 | ~90% sub-scale |
| 2025 funding | ~$0.70B / 54 deals | Down on 2024 (Inc42, 2026) |
| ABHA IDs issued | 93 crore+ | PIB, Jul 2026 |
| Health records linked | 104 crore+ | PIB, Jul 2026 |
| eSanjeevani consultations | 50.01 crore | MoHFW, Sep 2026 |
| Metric | Value | Basis |
|---|---|---|
| Market-to-projection multiple | ~6× | ~$17B → $100B+ by 2033 |
| Teleconsult CAC : consult value | ~2–6× | ₹800–2,000 CAC vs ₹300–800 value |
| Top-5 revenue concentration | ~60% | Teleconsult & e-pharmacy |
| Sub-scale share of base | ~90% | Pre-revenue or sub-₹1 cr |
| Expected attrition (2 yrs) | 20–30% | Fail or be acquired |
| Healthtech VC to medtech/dx | ~30% | Segment rotation |
| ABHA penetration | ~60% | ~85 cr of ~1.4B population |
| Health share of non-life insurance | ~41% | Largest non-life segment (FY25) |
| Clinician AI adoption | 12% → 41% | 2024 → 2025 |
How this edition was built, what it draws on, and the terms it uses.
Volge Quarterly synthesises Volge's running intelligence into a dated, falsifiable read of the year. Market data is reconciled across multiple third-party sources; where they disagree on scope, a range is given rather than a single point estimate. Each Call is written to be falsifiable, dated to a resolution year, and confidence-rated. The 2028 edition will grade every Call hit, miss or partial, and report a running hit-rate by confidence band.
Custom Market Insights and Mordor Intelligence (market sizing); National Health Authority / ABDM dashboard (rails, January 2026); Ministry of Health & Family Welfare and Digital Health News (eSanjeevani, November 2025); IRDAI (insurance); Tracxn, Inc42, Entrackr and company filings (funding, revenue, deals, 2024–26); EY, PIB and Rest of World (generative AI). Figures current to June 2026. Underlying detail is held in Volge's internal sector playbook.
ABDM: Ayushman Bharat Digital Mission; the national health-identity and interoperability layer. ABHA: Ayushman Bharat Health Account; the portable health ID issued under ABDM. CAC / LTV: customer-acquisition cost; lifetime value. Their ratio governs survival. eSanjeevani: the Government's national telemedicine service; the world's largest. DPDP: the Digital Personal Data Protection Act 2023 and its Rules. UHI: Unified Health Interface; the open discovery-and-booking network, the 'UPI for health'. SaMD: Software as a Medical Device; clinical AI regulated by CDSCO.
Five risks recur across the sector. None is fatal individually; together they raise the bar on execution, and each has a known mitigation.
| Risk | Mitigation |
|---|---|
| Crowded market with funded incumbents | Find a defensible niche; differentiate on execution, not idea |
| CAC exceeds LTV at scale | Validate unit economics early with cohort analysis; model scenarios before scaling |
| Regulatory change (telemedicine, e-pharmacy, data) | Monitor developments; build a clinical and regulatory function; engage policy bodies early |
| Reimbursement dependence | Diversify revenue; keep a strong out-of-pocket baseline; avoid single-payer reliance |
| Trust & safety (quality, breaches) | Rigorous provider vetting; security from day one; liability insurance; transparent incident response |
The standing risk register for the sector. Current to June 2026.
The through-line of the register is that the sector's risks are concentrated not in the technology but in the model: who pays, how the customer is acquired, and whether the regulatory ground is firm. A venture that has answered those three questions has retired most of the risk that actually kills digital-health businesses.
The core team needs four capabilities, and the compliance function is non-negotiable from the start.
Healthcare domain expertise in a founder or co-founder (clinical, operational or policy) for credibility with providers and regulators. Technology and product built mobile-first and for ABDM interoperability. Operations and growth that understand India's regulatory, reimbursement and distribution complexity. Finance and compliance from day one, given data-privacy and medical-registration obligations.
Teleconsultation: doctors registered in the relevant state; Telemedicine Guidelines 2020 on consent, prescriptions and records. E-pharmacy: a pharmacy licence to dispense; prescription verification; cold chain maintained. Diagnostics: NABL or ISO 15189 accreditation; trained phlebotomists; clinical validation of reports. Clinical AI: CDSCO approval where the software is a medical device; positioned as decision support, not standalone diagnosis. Data & ABDM: explicit consent and deletion rights under DPDP; data localisation; penalties up to ₹250 crore.
Hiring for scale before the model is validated; skipping compliance hires; and building product without clinical input. Each is avoidable, and each is fatal often enough to be worth naming.
The edition compressed: where the sector stands, what moves it, and what to watch.
A ~$15–18 billion market on a base of ~11,000 mostly sub-scale firms, built on severe care undersupply and the ABDM public rails, gated by unit economics rather than capital or regulation.
The unit-economics reckoning: growth stops being funded; the models that repay survive. Distribution shifts to the free channels: corporate, government, ABDM. Compliance under DPDP becomes a moat and a deal gate. The payer deepens (health insurance,
OPD and group cover), loosening the CAC trap. Value migrates down the acuity curve to chronic-care, provider software and infrastructure. Frugal, sovereign AI cuts the cost to serve and stretches the scarce clinician.
The e-pharmacy notification, PM-JAY reimbursement expansion, IRDAI moves on OPD and group cover, the first profitable platform quarter, and the first credible pure-play IPO. Move any of these and the year moves with it.
2027 does not decide whether Indian digital health succeeds: the structural demand settles that. It decides who succeeds, and on whose money. The winners are already visible in their unit economics.
The signals to watch through the year: the seed of next year's Calls.
DPDP Rules enforcement timeline as it applies to health data. ABDM transaction volumes, not account counts: the test of whether the rails carry real traffic. The e-pharmacy notification, pending since 2018 and court-directed since 2023. PM-JAY teleconsultation reimbursement expansion beyond select states. IRDAI moves on out-patient and group cover: the payer-deepening signal. Clinical acceptance and any reimbursement of AI-scribe and diagnostic-copilot outputs. The first credible pure-play digital-health IPO, and whether it prints on cash-flow positivity. Consolidation pace among teleconsultation players as the unit-economics squeeze plays out.
The 2028 edition opens with the Scorecard: each of these ten Calls graded hit, miss or partial, with a running hit-rate by confidence band. A forward-look that refuses to mark its own homework is just a brochure; Volge Quarterly marks it.
Volge Quarterly is Volge's signature series, published every quarter for enterprise customers. Each edition takes one subject, sets out where it currently stands on the published record, and makes a set of dated, falsifiable judgements on where it is going, written to give a buyer something firmer than a forecast: every figure carries its source and its date, every judgement carries the date on which it resolves, and the following year's edition grades each one hit, missed or partial.
Where a figure is not published, the edition says so rather than estimating it. Where published sources disagree, both are given and the disagreement is stated rather than averaged away. A number that does not survive checking is corrected here rather than repeated.
The edition carries no recommendation of any supplier and no offer of service. Where a vendor, platform or deployment is named it is because it is part of the published record of the subject.
This edition may be shared freely. It may not be altered or republished without permission, and figures carry their stated basis and date. Names and marks appearing in it are the property of their respective owners.